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Huntington’s disease (HD) is a progressive neurodegenerative disorder that causes involuntary muscle movements, 
deteriorates muscle coordination and cognitive decline. Typical onset age of the disease is in mid-age, although 
a juvenile form of HD is also known. The disease is inherited in an autosomal dominant manner via a mutation in 
the huntingtin gene (HTT). The characteristic mutation in HTT is an expansion of the glutamine stretch at the 5’ 
end of the gene. Excessive amounts of glutamine residues alters the conformation and chemical features of the 
huntingtin protein (HTT) leading to accumulation of cellular aggregates. Although to date there are several known 
alterations in the cell that contribute to the disease, the pathogenesis of HD is not fully understood.  
 
Ubiquitin-proteasome system (UPS) dismantles proteolytically unneeded or damaged proteins, which are targeted 
to proteolysis when ubiquitin tags are added to them. Deubiquitinating enzymes (DUB) recycle ubiquitin molecules 
by releasing them from proteasome substrates. Recycling of ubiquitin is critical to a cell as it maintains the free 
pool of the targeting molecule. Ubiquitin-specific protease 14 (USP14) is one of the DUB family enzymes and its 
distinctive function is to remove ubiquitin molecules from the tip of the ubiquitin chain and thus antagonize protein 
degradation. Although the specific function of the protein is unclear, it seems that USP14 operates as a fine 
regulator of protein turnover rate and in ER stress both in catalytic and non-catalytic manner. The role of USP14 is 
especially emphasized in the nervous system, as it regulates synaptic transmission and neuronal development. 
Although it is suggested that dysfunction of UPS is involved in the pathogenesis of HD, the role of USP14 in the 
disease remains to be unknown. IU1 is a novel inhibitor of the catalytic domain of USP14. Studies with IU1 
indicate that inhibition of USP14 enhances the clearance of aggregate-prone proteins.  
 
The approach of this thesis was aimed to elucidate the routes of HD pathogenesis from diverse approaches. The 
general aim of the thesis was to investigate the role of USP14 in the wild-type PC6.3 cell model, and in the 
pathogenesis of HD by expressing HTT proteins with different lengths of glutamine stretches in PC6.3 cells. The 
specific aim of the study was to examine by western blot and microscopy analysis the pathogenic routes of HD that 
involve ER stress, oxidative stress, autophagy and mutant HTT aggregate dynamics. The function of USP14 was 
studied with overexpression of USP14, or by inhibiting its catalytic activity by IU1.  
 
The findings of this thesis show that overexpression of USP14 enhances the clearance of mutant HTT aggregates, 
and this effect is obtained in catalytic activity dependent manner. I show that upregulated USP14 is connected to 
improved clearance of mutant HTT and inhibition of autophagy, suggesting that the degradation is mediated via 
UPS. The catalytic activity of USP14 might also be important in ER stress regulation, as the results indicate that 
IU1 activates phosphorylation of both JNK and eIF2α. I was also able to establish a connection between USP14 
and GADD34, as I show that GADD34 upregulates USP14. Finally, I show that catalytic inhibition of USP14 
decreases the expression of antioxidant SOD2. The data in this thesis is lacking statistical significance, and it can 
be considered solely as a guideline. However, together these results indicate that the deubiquitinating activity of 
USP14 increases survival in PC6.3 cells in both a healthy and a HD model.  
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Huntingtonin tauti (HD) on progressiivinen hermostorappeumatauti, joka aiheuttaa pakkoliikkeitä, 
lihaskoordinaation rappeutumista sekä kognition heikkenemistä. Vaikka tyypillisesti oireet alkavat keski-iässä, 
Huntingtonin taudista tunnetaan myös nuoruudessa puhkeava muoto. Tautia aiheuttava mutaatio 
huntingtiini-geenissä (HTT) periytyy vallitsevasti kromosomissa 4. HTT-geenin 5’ päässä oleva mutaatio aiheuttaa 
CAG-toistojakson monistuman. Mutaatio muuttaa huntingtiini-proteiinin (HTT) laskostumista sekä kemiallisia 
ominaisuuksia, mikä johtaa solun sisäisten HTT-aggregaattien kerääntymiseen. Vaikka tiedetään, että Huntingtonin 
tautiin liittyvät useat solun sisäiset muutokset, sen syntymekanismia ei tarkalleen tunneta. 
 
Ubikitiini-proteasomi-systeemi (UPS) hajottaa solussa proteolyyttisesti tarpeettomia tai vaurioituneita proteiineja, 
jotka on kohdennettu systeemiin ubikitiinimolekyyleillä. Ubikitiinia poistavat entsyymit (DUB) irrottavat 
ubikitiinia proteiinisubstraateista ja vapauttavat sen solulimaan. Ubikitiinin kierrätys on tärkeä prosessi solun 
aineenvaihdunnassa, sillä se ylläpitää vapaan ubikiitinin määrää. Ubikitiinille spesifinen proteaasi 14 (USP14) 
kuuluu DUB-proteiiniperheeseen ja poistaa ketjuuntunutta ubikitiinia sen distaalisesta päästä yksi kerrallaan 
hidastaen proteolyysiä. Vaikka tiedetään, että USP14 toimii proteiinien hajotuksen hienosäätelijänä sekä 
katalyyttisesti että ei-katalyyttisesti, sen tarkkaa mekanismia ei vielä tunneta. On myös osoitettu, että USP14 estää 
ER-stressiä katalyyttisen ja ei-katalyyttisen mekanismin avulla. Tiedetään, että USP14-proteiinilla on tärkeä rooli 
hermostossa, sillä se säätelee synaptista välitystä ja hermoston kehittymistä. USP14-proteiinin roolia ei ole tutkittu 
Huntingtonin taudissa, vaikka oletetaan, että UPS:n toimintahäiriöt liittyvät taudin patogeneesiin. IU1 on uusi 
USP14-proteiinin katalyyttisen alayksikön estäjä. Tutkimukset ovat osoittaneet, että USP14-proteiinin 
katalyyttinen estäminen IU1-molekyylillä tehostaa proteiiniaggregaattien hajottamista solussa. 
 
Tämän Pro gradu -tutkielman ja siihen liittyvien kokeiden tavoitteena oli tutkia Huntingtonin taudin patogeneesiä 
useista eri lähtökohdista. Yleinen tavoite oli tutkia tautia USP14-proteiinin viitekehyksestä sekä villityypin 
PC6.3-soluilla että HD-mallin soluilla, joissa ilmennettiin eripituisia CAG-toistojaksoja huntingtiini-plasmidien 
avulla. Pro gradu -tutkielmassa keskityttiin erityisesti tutkimaan Huntingtonin taudin patogeneettisistä reiteistä 
ER-stressiä, oksidatiivista stressiä, autofagiaa ja mutantti-HTT-proteiinin aggregaattidynamiikkaa. Menetelminä 
käytettiin western blot -menetelmää ja mikroskooppianalyysiä. USP14-proteiinin toimintaa tutkittiin 
yli-ilmentämisellä tai estämällä sen katalyyttinen aktiivisuus IU1-molekyylillä. 
 
Tutkielmassa olevat löydöt osoittavat, että USP14-proteiinin yli-ilmentäminen tehostaa mutantti-HTT-proteiinin 
hävittämistä solusta mekanismilla, joka on riippuvainen katalyyttisestä aktiivisuudesta. Korkeampi 
USP14-proteiinin määrä on yhteydessä sekä tehostuneeseen mutantti-HTT-proteiinin hajoitukseen että autofagian 
estämiseen. Tämä viittaa siihen, että mutantti-HTT-proteiinin vähentyminen on kytkeytynyt UPS:iin. 
Tutkielmassani näytän myös, että USP14-proteiinin katalyyttinen aktiivisuus voi olla tärkeä ER-stressin säätelyssä, 
sillä IU1 aktivoi ER-stressiproteiinien JNK ja eIF2α fosforylaatiota. Tulokseni osoittavat lisäksi, että GADD34 
yli-ilmentäminen PC6.3-soluissa lisää USP14-proteiinin määrä. On mahdollista, että USP14 vaikuttaa myös 
antioksidanttitasolla solussa, sillä tulosteni perusteella USP14-proteiinin katalyyttinen estäminen vähentää 
SOD2-proteiinin ilmentymistä. Tutkielmassa esitetyistä tuloksista puuttuu tilastollista varmuutta ja niitä voidaan 
pitää lähinnä suuntaa antavina. Yhdessä nämä tulokset kuitenkin osoittavat, että USP14-proteiinin ubikitiinia 
poistava aktiivisuus lisää solun selviytymismahdollisuuksia sekä terveessä solussa että HD-solumallissa.  
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1 INTRODUCTION 
 Huntington’s disease 
Huntington’s disease (HD) is a progressive neurodegenerative disease caused by protein 
misfolding. HD is named after George Huntington who described it as a hereditary chorea 
(the word chorea is derived from an ancient Greek word for dance) and showed that its 
pattern of inheritance is autosomal dominant (Huntington 1872). The prevalence of 
Huntington’s disease in the Western Europe and North America is 4–10 per 100 000 
(Walker 2007, Ross and Tabrizi 2011).  
 
The age of onset, rate of progression and the symptoms in HD vary greatly between 
individuals. The mean age of onset is 40, but it can occur between ages 1 to 80 
(Myers 2004) and before the onset there are no detectable symptoms of HD (Walker 2007, 
Ross and Tabrizi 2011). Eventually the healthy period merges with the prediagnostic 
period, in which mild symptoms ranging from slight changes in personality and cognition 
to motor control, are beginning to show. Cognitive dysfunction becomes more severe as 
the disease progresses causing impairment in executive functions, such as speech and 
short-term memory. Psychiatric problems leading to depression and suicide are also 
prevalent in HD. Chorea, which can be seen as brief and random uncontrollable movement, 
is coupled to the diagnostic phase of the disease (Walker 2007, Ross and Tabrizi 2011).  
The impairment of the motor skills is associated with later phases of HD progression and 
can be observed as an inability to maintain a voluntary muscle contraction, which 
eventually leads to changes in position. Death usually occurs in 20 years from diagnosis 
and it is primary due to cardiovascular diseases and pneumonia, difficulties of swallowing, 
complications from falls and also suicides (Sorensen and Fenger 1992, Walker 2007). 
 
Although HD affects the whole brain, the hallmarks of the disease are serious atrophy and 
cell death in the neostratium which includes caudate nucleus and putamen 
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(Ferrante et al. 1985). The striatal GABAergic medium sized spiny neurons are most 
vulnerable to neuronal death, which provides the neurobiological basis for chorea (Mitchell 
et al. 1999). Other affected areas in the brain include substantia nigra, hippocampus, 
purkinje cells in the cerebellum, lateral tuberal nuclei of the hypothalamus and parts of the 
thalamus (Walker 2007). The abnormalities in HD are seen also outside the central nervous 
system (CNS) and they are not always secondary to brain dysfunction. It seems that the 
ubiquitous expression of mutant huntingtin (mHTT) in the peripheral tissues is associated 
with symptoms such as weight loss and skeletal muscle wasting, which may contribute to 
the pathogenesis (van der Burg et al. 2009).  
 Medical diagnosis and treatment 
The diagnosis of HD is usually based on family history and physical symptoms 
(Walker 2007). Neuroimaging studies, like positron emission tomography and functional 
magnetic resonance studies, can be used to confirm the diagnosis and estimate the onset of 
the disease. The diagnosis is usually confirmed with genetic testing, which is used to detect 
the carrier status of an individual in presymptomatic, symptomatic or prenatal phase of HD 
(Myers 2004).  
 
In Finland the testing begun in 19881 and it is executed in prediagnostic manner. The 
genetic counseling aims to assist individuals to form an autonomous choice to the testing 
the disease, which may have long-term familiar effects. From my personal working 
experience between years the 2011–2014, the genetic testing performed at HUSLAB is 
based on PCR and the results are confirmed by sequencing. The method detects the sizes of 
the HTT 5’ end alleles, which are compared to known negative and positive control 
samples. The comparison is first executed by PCR in which DNA extracted from 
peripheral blood is amplified. The amplification products are analyzed by gel 
electrophoresis and the product sizes are compared to known negative and positive control. 
The sequence is analyzed with automated genotyping software and the glutamine codon 
(CAG) repeat count can be calculated. 
                                                 
1 http://www.vaestoliitto.fi/@Bin/628501/HD+ennustava+geenitestaus+30.6.2010+doc.pdf 
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There is no cure or treatment for HD and the currently existing pharmaceutical treatments 
can only relieve some of the symptoms (Walker 2007). The drugs that are currently used in 
the treatment of HD are targeting chorea and behavioral dysfunction (Ross and 
Tabrizi 2011). Tetrabenazine is commonly used to relieve chorea (Huntington Study Group 
2006). Psychiatric and behavioral problems are treated with commonly used 
antidepressants and antipsychotic drugs which are combined with psychological 
counseling (Nance 2012).  
 Genetic background  
The pathogenesis of HD is caused by a dynamic mutation in the huntingtin gene (HTT), 
which was mapped in 1983 to the tip of the short arm of chromosome 4 (4p16.3) (Gusella 
et al. 1983) and later isolated in 1993 by haplotype analysis of linkage disequilibrium (The 
Huntington's Disease Collaborative Research Group 1993). The genetic alteration that 
causes the pathogenesis in HD is an expanded unstable polyQ (polyglutamine) in the 
coding region of the first exon of the HTT. In 1994 it was found that the gene spans 180 kb 
and contains 67 exons ranging in size (Ambrose et al. 1994). To date there have not been 
systematic or sufficiently extensive linkage studies to determine the additional candidate 
genes that are associated with the pathogenesis. 
 
The allele is considered as a wild-type when it encodes 6 to 35 repeats of CAG, while more 
than 36 repeats in an allele determines the diseases causing gene (Rubinsztein et al. 1996) 
(Table 1). Penetrance increases as the number of repeats increases: incomplete penetrance 
is associated with 36–40 repeats, while more than 41 repeats causes full penetrance of HD.  
 
The length of polyQ correlates with the age of onset, rate of progression and the penetrance 
of HD. The onset is age dependent, and more than 40 CAG is associated with full 
penetrance by the age of 65 years (Langbehn et al. 2004).  Also the rate of deterioration of 
cognitive and motor measures increases with longer polyQ stretch (Rosenblatt et al. 2006). 
It is suggested, that the progression of psychiatric symptoms and behavioral problems does 
not have correlation to the length of repetitions (Ravina et al. 2008). The variation in the 
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age of onset is approximately 60% with the remainder determined by environment and 
inheritance (Walker 2007). Also, homozygotes appear to have an accelerated rate of 
progression (Squitieri et al. 2003). 
 
 
Table 1. The type of huntingtin alleles and their implication to pathogenesis of 
Huntington’s disease. The augmented CAG count causes elevated risk of getting HD 
due to the nature of alleles and the increasing of penetrance. Huntington’s disease 
(HD), wild-type (wt). 
(CAG)n HD ALLELE TYPE PENETRANCE INHERITANCE 
< 27 Wt – – 
28–35 Unstable wt – Elevated risk 
36–40 Mutated Incomplete 50% 
> 40 Mutated Full 50% 
 
 
Alleles with more than 28 repeats are so called intermediate alleles. They show instability 
in replication and are more likely to be elongated (Walker 2007). The unstable nature of 
polyQ is emphasized in every successive generation: the longer the repeat, the more 
unstable it is during meiosis. Paternal inheritance is often associated with large repetition 
sizes (Trottier et al. 1994, Ranen et al. 1995). There are also cases in which the disease has 
been manifested without any known family history. This is typically due to an expansion in 
an allele that is on the borderline of a normal range of CAG repeats. Usually this is also 
associated with paternal spermatogenetic instability (Walker 2007). 
 
The juvenile form of HD is defined by the onset of symptoms before 20 years of age and it 
comprises less than 10% of all HD cases (Nance and Myers 2001). It is associated with 
large (more than 60) CAG repeats in the HTT and it is transmitted from the HD-affected 
father (Nance and Myers 2001). Juvenile HD usually progresses faster, and the symptoms 
differ from the adult form in a way that chorea is usually exhibited only briefly with 
rigidity being the dominant symptom (Walker 2007).  
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 Huntingtin 
Huntingtin (HTT), a large soluble protein composed of 3144 amino acids, is the gene 
product of HTT (Hoogeveen et al. 1993, The Huntington's Disease Collaborative Research 
Group 1993). The predicted mass of the protein is 350 kDa, but it varies depending on the 
number of CAG residues.  
 
The structure of HTT can be divided to several parts that define the main function of the 
protein (Cattaneo et al. 2005, Ross and Tabrizi 2011) (Figure 1). The polyQ stretch starts at 
the 18th amino acid from the N-terminal. It is followed by a polyproline stretch which 
assists the solubility of the protein. Downstream from the polyproline stretch follow the 
multiple HEAT repeats (acronym for proteins that include the domain: HTT, Elongation 
factor 3, the PR65/A subunit of protein phosphatase 2A, and the yeast PI3-kinase TOR1) 
which take part in protein-protein interaction. HTT also has three conserved cleavage sites 
for proteases. After biosynthesis the protein undergoes extensive post-translational 
modifications that define a part of its function.  
 
 
 
 
Figure 1. Domain structure of huntingtin (HTT). HTT is a large protein composed of 3144 amino 
acids (aa) with several highly conserved protein domains. The polyQ (CAG)n stretch is located at the 
N-terminal of the protein, 36 or more CAG residues in the stretch cause HD. Downstream from the (CAG)n 
region lays the proline-rich sequence (polyP). There are several sets of HEAT repeats that stretch throughout 
a large portion of the polypeptide. Along the polypeptide there are also many protease cleavage sites that 
form the toxic N-terminal fragments. Also, many post-translational modifications alter the biochemical 
properties and toxicity of HTT. 
 
 
HTT is produced ubiquitously in human tissues. The highest concentration of the protein is 
in the brain and testes, moderate amounts being found in the liver, lungs and heart 
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(DiFiglia et al. 1995, Sharp et al. 1995). It is located widely inside the cell as it is found 
within the cell body, nucleus, dendrites and axons. It is associated with various organelles 
including Golgi apparatus, mitochondria and ER (DiFiglia et al. 1995, Landles and Bates 
2004).  
 
To date the function of HTT is not completely understood. It interacts with proteins which 
are associated with embryonic development, neuronal function, cytoskeletal motor 
transport and gene transcription (Ross and Tabrizi 2011, Cattaneo et al. 2005). It may have 
a role in RNA trafficking as well (Savas et al. 2010).  
 Molecular pathogenesis of Huntington’s disease 
The links between HTT and the pathogenesis of HD are not understood and it is likely that 
several mechanisms contribute to the pathogenesis (Figure 2). The current evidence 
suggests that the pathogenic gain- and loss-of-function mutations of HTT alter the folding 
and hence the properties of the protein (Tobin and Signer 2000, Shao and Diamond 2007).  
 
It has been proposed that one of the key mediators of striatal cell death in HD is impaired 
(brain-derived neurotrophic factor) BDNF trafficking (Gauthier et al. 2004, Ross and 
Tabrizi 2011). Since HTT is associated with vesicle recycling, the aggregation of mHTT 
might disrupt normal synaptic transmission. The transcription of BDNF has been shown to 
be decreased in HD (Zuccato et al. 2001). 
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Figure 2. Mechanisms that contribute to the pathogenesis of HD. 1. The polyQ stretch alters the 
conformation of HTT, which changes the properties of the protein and enhances the aggregation process. 
Proteolytic cleavage of mutant huntingtin (mHTT) produces N-terminal polypeptides which are considered as 
the most toxic forms of mHTT. The inclusion bodies are translocated to the nucleus in which they 
interference transcription of several genes. 2. The mutation in HTT disrupts vesicle transport, which has been 
associated with altered synaptic transmission. 3. Innate immunity is upregulated in HD, which is seen as 
activation of peripheral immune system and microglial cells in CNS. 4–7. Impaired clearance of mHTT is 
associated with HD pathogenesis that in turn provokes ER stress and oxidative stress. This thesis focuses on 
the mechanisms in circles 4–7 that are discussed in more detail later in the corresponding chapters. 
 
 
Aggregation of mutant huntingtin 
 
The normal structure of the HTT exon 1 encoded domain consists of a flexible N-terminal 
α-helix in which the polyQ region adopts coiled conformations (Kim et al. 2009). To date 
it is not known how the expansion in CAG alters the properties of the full-length HTT, but 
it is suggested that it leads to stacked β-sheet conformation (Poirier et al. 2005). Although 
it is believed that large full-length inclusions are not the primary cause of the disease, the 
conformation change is believed to increase HTT pathogenesis and aggregate formation of 
the protein (Ross and Tabrizi 2011).  
 
In 1997 it was found that N-terminal fragments of mHTT localize in the cortex and 
striatum as intranuclear inclusions, and the length of polyQ influences the accumulation of 
the peptide (DiFiglia et al. 1997). Currently it is believed that proteolytic cleavage, 
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producing this truncated form of HTT, is one of the key mediators of HD pathogenesis. 
Caspases can mediate the cleavage of mHTT at several places generating peptides with 
different lengths, which can adopt stacked β-sheet conformations and form aggregates 
(Ross and Tabrizi 2011). Currently it is not known which cleavage sites produce the toxic 
proteins in HD. The N-terminal aggregates are mostly found in the nucleus of neuronal 
cells but they are also localized in the cytoplasm, dendrites and axon terminals 
(Vonsattel 2008). It has been suggested that mHTT inclusions become toxic peptides when 
they are translocated to the nucleus in which they influence the transcription of several 
genes (Ross and Tabrizi 2011). The aggregation is a complex and not well understood 
process. It is plausible that mHTT may obtain several different conformations, in which 
soluble and intermediate proteins are likely to be the most toxic species to neurons (Kim et 
al. 2009). 
 
Impaired clearance 
 
Impaired clearance followed by accumulation of toxic protein aggregates is considered to 
be the main contributor to HD pathogenesis (Ross and Tabrizi 2011).  Misfolded proteins 
are removed primarily by the ubiquitin-proteasome system (UPS) and autophagy. UPS 
degrades predominantly short-lived proteins and autophagy long-lived cytoplasmic 
proteins or dysfunctional organelles (Li and Li 2011). The two degradative mechanisms 
can be separated by their activity in the cell: The activity of UPS is usually high in the cells 
whereas autophagy occurs at low basal level (Levine and Kroemer 2008). It is suggested 
that both autophagy and UPS are impaired in HD (Figure 3).  
 
It has been shown in various models that UPS is involved in mHTT processing, as polyQ 
plaques are stained positively against both proteasomes and ubiquitin in the nucleus and in 
the cytoplasm (Davies et al. 1997, DiFiglia et al. 1997, Waelter et al. 2001). However, 
there is no clear understanding how mHTT is cleared in the cell, or what is the role of 
proteasomes in the pathogenesis of HD. The contribution of UPS remains controversial, 
since it is unknown whether proteasomes degrade nuclear mHTT fragments, generate toxic 
inclusion bodies, or in worst case become clogged and impaired by the aggregates. 
Although the role of UPS impairment in HD pathogenesis has been investigated heavily in 
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the past years, the data remains controversial, which is possibly due to many different 
experimental approaches (Imarisio et al. 2008, Li and Li 2011). Theories, which are 
suggesting that accumulation of toxic mHTT species and dysfunction of UPS are coupled 
manifestations of HD, are clarified as the knowledge of the pathogenesis increases. 
 
 
 
 
Figure 3. Crosstalk between autophagy and UPS in HD. The accumulation of mHTT in the cell is linked 
to impaired protein degradation machinery, ergo UPS and autophagy. The connection between UPS and 
autophagy remains unknown in HD pathogenesis. The increased load of toxic mHTT leads to ER stress via 
UPR. This also stimulates oxidative stress responses in a cell. These events are proposed to couple the two 
degradative pathways together, though the signaling routes are currently unknown. 
 
 
Autophagy inhibition leads to accumulation of polyubiquitinated aggregates, indicating 
that UPS substrates are degraded also via autophagy (Komatsu et al. 2006). However, 
inhibition of macroautophagy does not upregulate UPS but instead compromises its 
function (Korolchuk et al. 2009). Conversely, acute inhibition of proteasomal function 
upregulates macroautophagy (Iwata et al. 2005, Pandey et al. 2007). It is suggested, that 
autophagy could function as a backup system for UPS. When compared to UPS, autophagy 
degrades more efficiently the aggregated forms of mHTT. In order to fit into the narrow 
pore of the proteasome barrel, the plaques must first be unfolded, which is slow and may 
be impossible (Levine and Kroemer 2008, Li and Li 2011). However, UPS is ubiquitously 
present in all cellular compartments including nucleus in which most of the mHTT 
inclusion bodies are found, whereas autophagy is operating exclusively in the cytoplasm 
(Bader et al. 2007, Ross and Tabrizi 2011).   
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The connection between these two distinct degradation mechanisms remains unknown 
(Figure 3). Several potential explanations have been presented, but currently there is no 
consensus on the matter (Korolchuk et al. 2010). Although the exact mechanism is not 
known, one conjunctive mechanism involves the activation of ER stress due to the 
accumulation of misfolded mHTT. This is suggested to be dependent on the stimulus for 
unfolded protein response (UPR) and cell type (Korolchuk et al. 2010). Both autophagy 
and UPS are sensitive to oxidative stress that is generated in the progression of HD (Cui et 
al. 2006, Levine and Kroemer 2008, Li and Li 2011).  
1.1.4.1 The role of immune system in the pathogenesis 
There is growing evidence that inflammatory responses are a critical part of the 
pathogenesis of HD, although the mechanisms are still not fully understood. There are 
several reports indicating that innate immunity responses are evoked in HD pathogenesis. 
However, it is not known whether or not inflammation is the cause or consequence of 
neurodegeneration (Soulet and Cicchetti 2011). 
 
Microglial cells contribute to the innate immune response when they are activated 
(Streit 2002). A typical marker of neuroinflammation in neurodegenerative diseases is the 
presence of activated microglial cells in the CNS (Lobsiger and Cleveland 2007). The 
activation of microglial cells is associated with mHTT expression, which can be seen in the 
brains of presymptomatic HD patients and predicts progression of the disease (Shin et al. 
2005, Tai et al. 2007). It is speculated that the activation of microglial cells may contribute 
to neurodegeneration by generation of free radicals, excitotoxicity and caspase activation 
(Soulet and Cicchetti 2011). 
 
The inflammatory responses are not only restricted to CNS in HD patients. It has been 
confirmed, that the peripheral immune system is also activated in HD (Bjorkqvist et al. 
2008). Innate immunity responses are seen in HD as impaired migration of macrophages 
and monocytes (Kwan et al. 2012). This leads to chronic increase in proinflammatory 
cytokines and chemokines in the CNS as well as activation of microglial cells. The role of 
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the complement system is poorly known in HD, but the neurodegeneration seems to trigger 
the expression of complement factors (Singhrao et al. 1999).  
 
It is poorly known how these events are contributing to the pathogenesis of HD. One 
suggested mechanism is that neuronal cell death releases toxic mHTT that in turn acts as 
an antigen and evokes immune response (Soulet and Cicchetti 2011). 
 Research approaches 
Despite the 20 years since the discovery of the HTT mutation, much of the pathogenesis is 
still unknown, and fundamental questions remain. Several cellular and in vivo model 
systems have been developed to investigate HD. It is important to enhance these models in 
the future, for example by developing patient-derived cell models, in order to understand 
the complexity of the disease. The in vivo invertebrate models of HD include Drosophila 
and Caenorhabditis elegans, which can be used to examine the progressive behavioral 
changes and neurodegeneration (Bates and Hockly 2003). Mouse models are also vital in 
HD research. Indeed, the intranuclear inclusions of mHTT were first observed in the 
transgenic R6/2 mouse model, before their discovery in the human post-mortem brain 
(Mangiarini et al. 1996, Ross and Tabrizi 2011). Currently there are several mouse models 
expressing either N-terminal mHTT fragments or full-length mHTT. Large mammalian 
models such as pigs, sheep or monkeys are used to study behaviour and to test drug 
responses.  
 
Clinical trials aim to develop drugs which treat or slow the progression of the disease, and 
over the past 10 years there have been many attempts to develop medication for HD 
(Walker 2007, Ross and Tabrizi 2011). The trials have been shown to be challenging due 
to the nature of the disease, which is slow progression and clinical heterogeneity between 
patients (Ross and Tabrizi 2011). In addition, the post-mitotic nature of neurons combined 
with the need for crossing the blood-brain barrier complicates the development of 
medication. However, several potential therapeutics are under investigation in animal 
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models and in human clinical trials, which are targeting the different cellular pathways 
involved in the pathogenesis of HD (Ross and Tabrizi 2011, Sampaio et al. 2014). 
 
Since the pathogenic routes are extremely complex, it seems that several routes need to be 
targeted simultaneously in order to obtain relevant response in treatment (Ross and Tabrizi 
2011). Currently there are several suggested therapeutic strategies to target the disease 
(Table 2).  
 
 
Table 2. Therapeutic targets in HD research. Upregulating UPS and autophagy are the research questions 
in this thesis. 
TARGET STRATEGY 
Delay the onset - Development of clinical markers and biomarkers 
Reduce the amount of mHTT 
- Increase clearance by upregulating UPS and autophagy 
- Downregulate the expression by siRNA and antisense nucleotides 
Mitigate the toxicity of mHTT 
- Inhibition of proteolytic cleavage 
- Molecules that change the properties of mHTT 
Restore the lost neurons - Cell replacement strategies 
 
 
Ideally HD should be tackled at the early premanifest stage of the disease, when neuronal 
cell death has not occurred, and the onset could be delayed. One of the important research 
aspects focuses on identifying clinical markers and biomarkers to target and quantify the 
progression. However, preventive clinical trials are limited by lack of knowledge of the 
pathogenesis of HD.  Several indicators in over 1300 participants who are at risk of HD 
have been investigated aiming to find a way of intervention in the earliest possible phase of 
HD (Paulsen et al. 2014). Gene expression arrays aim to characterize suitable biomarkers 
for the progression of HD, since several alterations have been discovered in the HD exome 
(Cattaneo et al. 2005, Butler and Bates 2006, Hodges et al. 2006, Ross and Tabrizi 2011). 
Unfortunately there are not yet validated biomarkers for the disease (Ross et al. 2014).  
 
Upregulating the degradative pathways aim to clear the aggregate amount in neuronal 
cells. Despite that upregulating UPS is technically challenging, new promising agents are 
being investigated (Lee et al. 2010, Ross and Tabrizi 2011). Stimulation of autophagy is 
 
 
13 
 
considered as one of the most potential medical treatments for HD. Induction of autophagy 
with rapamycin, that inhibits mammalian target of rapamycin (mTOR), has proven to 
reduce the levels of soluble mHTT and formation of intracellular aggregates in fly and 
mouse models of HD (Ravikumar et al. 2002, Ravikumar et al. 2004). However, rapamycin 
might not be suitable for long-term treatment, since it has diverse autophagy-independent 
functions which affect immunosuppression and wound healing (Sarbassov et al. 2005). The 
currently known effective mTOR-independent autophagy inducers, which increase the 
clearance of mHTT, include lithium and trehalose (Sarkar et al. 2005, Sarkar et al. 2007). It 
has been suggested, that the most potential therapy uses simultaneously both 
mTOR-dependent and -independent strategies (Harris and Rubinsztein 2011). 
 
Reduction of the amount of mHTT is one promising target in the investigation. It has been 
shown in the transgenic mouse model, that downregulation of mHTT leads to partial 
recovery (Yamamoto et al. 2000). The production of the protein can be targeted also with 
small interfering RNA (siRNA) or antisense nucleotides (DiFiglia et al. 2007, Boudreau et 
al. 2009). The problem involving these methods lie in the function of the normal HTT, 
since it is currently unknown how much downregulation the brain can bare.  
 
One current line of investigation is to mitigate the toxic properties of mHTT. Inhibition of 
the proteolytic cleavage of mHTT by specific caspase inhibitors has been investigated (Cao 
et al. 2012). The aggregation process of mHTT may prove to be one potential factor in 
toxicity reduction, as agents that decrease the mHTT aggregation have been identified 
(Ehrnhoefer et al. 2008, Sontag et al. 2012). As the knowledge of mHTT dynamics and 
conformational structures increase, these agents can be designed more accurately. 
 
One of the recent stage strategies to treat HD is the replacement of damaged and/or lost 
neuronal cells by transplantation of stem cells into affected lesions of the brain. However, 
this approach is extremely challenging in several ways. The differentiation of embryonic 
stem cells or induced pluripotent stem cells to specific neuronal cell types is difficult to 
control (Ross and Tabrizi 2011). Also, gaining the correct functionality in the brain tissue 
and avoiding tumorous growth is a major challenge (Ross and Tabrizi 2011).  To date the 
clinical trials have been executed only with fetal donor tissue in the striatum, in which 
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transplantation provided moderate cognitive and motor function improvement to some of 
the HD patients (Bachoud-Levi et al. 2006). Despite the difficulties in the transplantation 
experiments, stem cells are a valuable and important tool in in vitro HD studies, and may 
provide us with novel restorative therapeutic alternatives in the future.  
 Cell death  
 Classification of cell death mechanisms 
Traditionally cell death mechanisms have been classified as programmed or 
non-programmed cell death, apoptosis and necrosis respectively. As the knowledge of the 
events in cell death is constantly growing, so is the spectrum of the modalities. In addition, 
the fundamental pathways are beginning to be more and more defined and intertwined. It 
has been proposed, that rather than looking at a cell’s morphological features in death, that 
it is more preferable to determine the molecular events in a dying cell and move towards 
functional classification between modalities (Galluzzi et al. 2012).  
 
Apoptosis 
 
Apoptosis (translates from Greek “leaves falling from a tree”) is a genetically programmed 
and evolutionally conserved mechanism of cell death. The basic function of apoptosis is to 
maintain cell count homeostasis in a non-immunogenic manner (Kerr 2002). The 
disturbances in apoptosis are associated with a vast number of disorders, including 
neurodegenerative diseases, cancer, immunity and cardiovascular system disorders 
(Hotchkiss et al. 2009). The morphological features of apoptosis are shrinkage of the cell, 
chromatin condensation and fragmentation, plasma membrane blebbing and at the final 
phase phagocytic engulfment of apoptotic bodies. Contrary to necrosis, the integrity of 
membranes and organelles persists intact during the process of dying (Kerr et al. 1972, 
Kroemer et al. 2009) The molecular classification of apoptosis includes activation of 
caspase proteases and mitochondrial outer membrane permeabilization, that leads to escape 
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of mitochondrial proteins and disruption of oxidative phosphorylation (Kroemer et al. 
2009, Galluzzi et al. 2012). However, the criteria of apoptosis are nevertheless evolving as 
the knowledge of the overlapping cell death mechanism is widened. Apoptosis is initiated 
by a response to diverse stress stimuli, such as oxidative and ER stress, toxins, growth 
factor insufficiency and DNA damage (Mattson and Chan 2003, Hotchkiss et al. 2009). 
Apoptosis is tightly regulated, primarily through the balance of anti- and pro-apoptotic 
proteins in the Bcl-2 (B-cell lymphoma 2) family (Danial and Korsmeyer 2004). 
 
Necrosis 
 
Necrosis (from the Greek word for death) is an accidental and irreversible response to 
extreme conditions external of the cell, such as toxins of infection. The morphological 
definition of necrosis is rapid swelling and disruption of cell membranes (Hotchkiss et al. 
2009). The loss of membrane stability allows influx of extracellular fluid and ions into 
intracellular space, which is followed by swelling of the organelles and the cell. Necrosis is 
also classified as a mechanism lacking the apoptotic and autophagic traits of cell death 
(Galluzzi et al. 2012). Recently it has been proposed that, conversely to what has been 
self-evident for a long time, necrosis can also occur in regulated manner in an event 
referred to as “necroptosis” (Galluzzi et al. 2012).  
 
Autophagy 
 
Autophagy (from the Greek words auto “on self” and phagy “to eat”) is an evolutionally 
highly conserved catabolic mechanism that operates at low basal level in virtually all 
eukaryotic cells. It involves bulk degradation of unnecessary or dysfunctional cytosolic 
proteins and organelles. Autophagy has an important role in many cellular processes from 
remodeling during embryogenesis to the length of life of an animal. Although autophagy is 
indeed a mechanism to adapt a cell to nutritional starvation by maintaining cellular energy 
levels, massive autophagy promotes cell death (Yorimitsu and Klionsky 2005, Levine and 
Kroemer 2008). 
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The separation between ongoing autophagy and autophagic cell death is rather 
problematic, since cells rarely die by autophagy itself. The current morphologic 
characterization of macroautophagy includes massive autophagic vacuolization of the 
cytoplasm and lack of chromatin condensation (Kroemer et al. 2009, Kroemer and Levine 
2008). The cell can be considered to encounter autophagic cell death only if death can be 
prevented by suppressing autophagy (Galluzzi et al. 2012). The autophagic pathway can be 
inhibited by altering the autophagic genes, by chemicals, and RNA interference to 
autophagic modulators. 
 
The known subforms of autophagy are micro- and macroautophagy and 
chaperone-mediated autophagy. Macroautophagy is a mechanism in which cytosolic 
particles are transported to lysosomes by autophagosomes, which are specialized double 
membrane organelles. The degradation is mediated by lysosomal hydrolases. 
Microautophagy is a non-selective mechanism which engulfs cytoplasmic matter by 
invagination of lysosomal membrane, whereas chaperone mediated autophagy degrades 
cytosolic proteins containing a particular pentapeptide consensus motif (Yorimitsu and 
Klionsky 2005). Upregulation of autophagy occurs via several stimuli such as starvation, 
environmental stress, cell density, ER stress and misfolded or aggregated proteins 
(Yorimitsu and Klionsky 2005, Ogata et al. 2006, Martinet et al. 2009, Levine and 
Kroemer 2008). 
 
The catabolic mechanism of autophagy (a.k.a. macroautophagy) can be divided into three 
phases, which reflect the formation of the autophagosome (Levine and Kroemer 2008, 
Yorimitsu and Klionsky 2005) (Figure 4). Autophagy is initiated when a vesicular 
structure, phagophore, begins to nucleate. This event is followed by elongation and the 
joining of the ends of the double membrane. Cytosolic matter is engulfed by the 
autophagosome during the nucleation process. One of the autophagosome-connected 
proteins is microtubule-associated protein 1 light chain 3 II (LC3-II), which is associated 
with the autophagosome, and required for the maturation process of the vesicle (Kabeya et 
al. 2000). In the second phase autophagosome and lysosome membranes are fused together 
forming an autolysosome (Levine and Kroemer 2008, Yorimitsu and Klionsky 2005). In 
the final step the inner membrane and the content of the vesicle are degraded with 
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lysosomal hydrolases. The free amino acids and fatty acids are released to the cytoplasm 
and recycled in the cell metabolism.  
 
 
 
 
Figure 4. Schematic representation of autolysosome formation during macroautophagy. 1. Phagophore 
nucleation is followed by vesicle elongation, growth and enclosure. During the maturation process cytosolic 
matter and organelles become engulfed by the maturating vesicle. Proteins that assist the nucleation process 
include LC3-II. 2. The membranes of mature autophagosome and lysosome are fused in a process that ends 
with autolysosome formation. 3. In the final phase of macroautophagy the content of autophagosomal matter 
is degraded with lysosomal hydrolases. 
 
 
One of the key regulators of autophagy is the kinase mTOR, which inhibits the formation 
of autophagosomes during abundant nutritional status and the presence of growth factors. 
Downstream of mTOR are autophagy related gene (Atg) products, which are an essential 
part of the execution of autophagy (Mizushima and Klionsky 2007). There are also several 
other molecules that regulate autophagy. One of the positive regulators of autophagy is 
rapamycin, which inhibits mTOR and induces autophagy (Blommaart et al. 1995). 
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 Autophagy in Huntington’s disease 
Cell death is thought to have an impact in HD in a programmed manner, apoptosis and 
autophagy being the best characterized cell death mechanisms contributing to 
pathogenesis. Most of the newly discovered mechanisms are somewhat overlapping 
derivatives of apoptosis and autophagy, and it is possible that they are also influencing HD. 
To date the evidence of the contribution of newer mechanisms to pathogenesis is still very 
scant, but it has been proposed, that for example necroptosis may participate in 
neurodegeneration (Vandenabeele et al. 2010). 
 
There are several studies pointing out that autophagy is an essential mechanism to prevent 
neurodegeneration. However, the data is still controversial. It is not known which 
contributes to neuronal cell death more, defective or excessive autophagy. The first 
association between autophagy and HD was observed in postmortem brains of HD patients 
in 1974 (Tellez-Nagel et al. 1974). To date the connection between HD pathogenesis and 
autophagy has been demonstrated in several models (Nixon and Yang 2012, Wong and 
Cuervo 2010). The dysfunction of autophagy has been linked to mHTT expression and 
aggregation in several studies, which point out that incompetent autophagy is increasing 
mHTT load leading to neurodegeneration (Komatsu et al. 2006, Hara et al. 2006). 
 
Cargo recognition failure is one of the proposed ways of autophagy inhibition in HD 
(Martinez-Vicente et al. 2010). The fusion of autophagosomes to lysosomes seems to 
operate in adequate level, while recognition of the cargo and engulfment of mHTT is 
failing. The underlying mechanism of the disturbance may involve Beclin-1, which 
participates in the autophagosome formation process (Kihara et al. 2001). The 
accumulating load of mHTT is binding to Beclin-1 that leads to its depletion (Shibata et al. 
2006).  
 
On a genetic level one of the failures could involve mutations in the dynein protein, which 
is involved in the transport of autophagosomes to lysosomes (Ravikumar et al. 2005, 
Roberts et al. 2013). The fusion of autophagosomes and lysosomes is compromised when 
the expression of dynein is decreased, which leads to accumulation of mHTT aggregates. It 
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has also been proposed, that mHTT is involved in dynein regulation decreasing the axonal 
transport of autophagosomes (Wong and Holzbaur 2014). 
 Oxidative stress in Huntington’s disease 
Reactive oxygen species (ROS) are produced as natural byproducts of oxygen metabolism 
(Finkel and Holbrook 2000, Balaban et al. 2005, Jones 2008). ROS are formed when 
molecular oxygen accepts free electrons, which are generated by normal metabolism. This 
produces highly reactive molecules. Cellular ROS include variety of diverse chemicals 
including superoxide anions, hydroxyl radicals and hydrogen peroxide. Among the most 
toxic species are superoxide radicals, which are extremely unstable. The homeostatic level 
of ROS is crucial for cells. Although ROS are needed in cellular metabolism and defense, 
the accumulation of ROS has several toxic effects. These effects include DNA 
fragmentation, oxidation of vital cellular molecules and cell death (Finkel and Holbrook 
2000, Balaban et al. 2005, Jones 2008).  
 
Antioxidants are molecules which counteract the excessive accumulation and toxicity of 
ROS (Finkel and Holbrook 2000, Balaban et al. 2005, Jones 2008) (Table 3). This group of 
enzymes includes superoxide dismutases (SOD) and thioredoxins (Trx). SODs are 
antioxidants that catalyze the breakdown of superoxide into oxygen and hydrogen 
peroxide. The intracellular SODs include SOD1 which is a copper-containing enzyme 
found primarily in the cytosol, and mitochondrial manganese-dependent SOD2. The three 
known forms of Trxs catalyze a reaction in which hydrogen peroxide breaks down to 
water.  
 
In oxidative stress the cell is unable to detoxify ROS or repair the damages that it has 
experienced (Finkel and Holbrook 2000, Balaban et al. 2005, Jones 2008). Prolonged 
oxidative stress leads to oxidative cellular damage and disruption of the thiol redox system. 
Macromolecular damage includes lipid peroxidation, protein modifications, mitochondrial 
dysfunction and DNA damage. These events are involved inter alia in aging, inflammation 
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processes, cardiovascular diseases, cancer and diabetes. Oxidative stress is also associated 
with neurodegenerative diseases. Several lines of research indicate that profound 
mitochondrial dysfunction and oxidative stress are involved in the pathogenesis of HD, 
although the mechanism of neuronal cell death and dysfunction in the disease remains 
unclear (Ross and Tabrizi 2011). 
 
 
Table 3. Chemical reaction equations of ROS detoxifying antioxidants. 
ANTIOXIDANT START PRODUCTS END PRODUCTS 
SODs 2 ·O2– + 2H+ H2O2 + O2 
Trx Trx(SH)2 + H2O2 TrxS2 + 2H2O 
 
 
Bioenergetic studies have revealed that complexes I–IV, which are the key components of 
oxidative phosphorylation, are reduced in activity in the striatal neurons of HD patients 
(Browne and Beal 2004). The decreased levels of ATP are also associated with the 
expanded CAG levels (Seong et al. 2005). It is suggested that mitochondrial function is 
impaired even in asymptomatic HD mutation carriers (Saft et al. 2005).  
 
Even if the entry of mHTT to the nucleus, which is followed by inhibition of transcription, 
is considered one of the key mechanisms for HD pathogenesis, the transcription of 
mitochondrial genes might also be affected (Ross and Tabrizi 2011). In 2006 it was found 
that the peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) is 
one of the central regulators of ROS detoxification (St-Pierre et al. 2006). PGC-1α 
enhances mitochondrial respiration and production of many antioxidants, including SOD2. 
PGC-1α is also one of the mitochondrial mediators in HD pathogenesis, since mHTT 
interferences PGC-1α expression (Cui et al. 2006, Chaturvedi et al. 2009, Weydt et al. 
2006). This is supported by the finding that the induction of PGC-1α is associated with 
elimination of mHTT aggregates (Tsunemi et al. 2012). Induction of oxidative stress in the 
disease is also seen in reduced activity of aconitase in the striatum of HD patients, due to 
elevated levels of nitric oxide in the cell (Tabrizi et al. 1999). There is also evidence of 
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DNA oxidation in HD patients as 8-hydroxydeoxyguanosine (8-OHdG), that is a marker of 
oxidized DNA, is increased in the frontal and parietal cerebral cortex of the post mortem 
HD patients (Polidori et al. 1999). 
 Endoplasmic reticulum stress in Huntington’s disease 
Endoplasmic reticulum (ER) has an important role in synthesis, folding, modification and 
transport of proteins. It regulates also intracellular calcium homeostasis and responses to 
cellular stress (Boyce and Yuan 2006, Hetz 2012, Rutkowski and Kaufman 2004). A 
variety of exo- and endogenous stimuli, including accumulation of misfolded proteins, 
lipid imbalances, pathogenic infection and nutrient deprivation, can cause dysfunction of 
ER. The dysfunction causes ER stress, in which protein metabolism is compromised, 
leading to accumulation of misfolded proteins, cell death and disease.  
 
Prolonged ER stress initiates UPR as a self-protective pathway, which aims to reduce the 
burden of unfolded proteins (Boyce and Yuan 2006, Hetz 2012, Rutkowski and Kaufman 
2004). There are several pro-survival mechanisms that are triggered by UPR, which are 
targeted to restore the normal cell function. These mechanisms activate ER luminal 
chaperone translation, which provides assistance to protein folding. These mechanisms 
induce ER associated degradation (ERAD) that eliminates ER luminal proteins and arrests 
general protein translation. During ERAD the misfolded proteins are degraded by the UPS. 
It has also been reported that UPR can trigger autophagic clearance of proteins (Bernales et 
al. 2006). If the homeostasis is not restored, the persistent ER stress can trigger apoptotic 
signaling cascade, which is followed by programmed cell death (Boyce and Yuan 2006, 
Hetz 2012, Rutkowski and Kaufman 2004).  
 
There are three ER-resident transmembrane sensor proteins which initiate UPR during ER 
stress:  inositol-requiring enzyme 1 (IRE1), protein kinase R (PKR)-like endoplasmic 
reticulum kinase (PERK) and activating transcription factor 6 (ATF6) (Boyce and Yuan 
2006, Hetz 2012, Rutkowski and Kaufman 2004) (Figure 5). The signal transduction is 
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induced by BIP/Grp70; immunoglobulin-binding protein, 78 kDa glucose-regulated protein 
(Bip), when it titrates away from the sensor proteins. The activation of IRE1 initiates 
pathways which activates factor X-box-binding protein (Xbp1) and the tumor necrosis 
factor receptor (TNFR)-associated factor 2 (TRAF2). Activated Xbp1 translocates to the 
nucleus and upregulates several pro-survival genes, which include proteins that promote 
ERAD and protein folding. TRAF2 activation triggers initiation of pro-apoptotic pathways. 
Among the pathways that are activated by phosphorylation is c-jun N-terminal kinase 
(JNK) (Urano et al. 2000). Besides apoptosis, JNK also triggers autophagy, which is 
induced by ER stress (Ogata et al. 2006). The PERK pathway is activated by 
phosphorylation of the eukaryotic initiating factor 2 alpha (eIF2α), which downregulates 
general protein synthesis (Boyce and Yuan 2006, Hetz 2012, Rutkowski and Kaufman 
2004). The downstream targets of the eIF2α pathway regulate antioxidant responses and 
amino acid metabolism, upregulate growth arrest and DNA damage-inducible gene 34 
(GADD34), and promote apoptosis and autophagy. Upon ER stress ATF6 is transported 
into the Golgi apparatus, where it is proteolytically cleaved. This releases its cytoplasmic 
domain fragment, which is now an active transcription factor. The activated ATF6 
fragment upregulates several genes including ERAD genes and components of Xbp1.  
 
In HD the mHTT accumulates in the nucleus and cytosol unlike in ER stress, in which 
proteins accumulate in the ER lumen (Rutkowski and Kaufman 2004, Ross and Tabrizi 
2011). Although the connection between HD pathogenesis and ER stress has been 
demonstrated, it is poorly understood what parts of the disease manifestation mechanisms 
are involved in ER stress pathways (Lindholm et al. 2006, Roussel et al. 2013). 
Disturbances in protein metabolism and ER stress are associated with HD: as a response to 
stress HTT is released from cell membranes and translocates to the nucleus (Atwal and 
Truant 2008). After the translocation HTT is exported and associated with ER. The 
expanded CAG tract inhibits the release leading to accumulation of mHTT in the nucleus, 
which causes perturbed ER. ERAD dysfunction is associated with HD when mHTT 
expression decreases the misfolded protein turnover rate and sensitizes cells to ER stress 
(Lajoie and Snapp 2011). The toxic effect of mHTT in ER stress is also associated with an 
impaired protein degradation rate via dysfunctional UPS (Bennett et al. 2007, Nishitoh et 
al. 2002). In addition, mHTT binds to ERAD proteins Ufd1, Npl4 and p97 and inhibits 
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their function leading to accumulation of ER luminal proteins in HD (Duennwald and 
Lindquist 2008). 
 
HD provokes cell death in ER stress-mediated pathways. Induction of apoptosis by mHTT 
is induced in ER stress, and is followed by activation of the IRE1 pathway via apoptosis 
signal-regulating kinase 1 (ASK1) (Nishitoh et al. 2002). ASK1 also enables mHTT 
translocation to the nucleus, resulting in atrophy and motor dysfunction (Cho et al. 2009). 
ER stress-associated apoptosis is also initiated when mHTT activates caspase 12 (Kouroku 
et al. 2002). ER stress-induced autophagy has been shown to be associated with HD via the 
PERK/eIF2α pathway (Kouroku et al. 2007). 
 
 
 
 
Figure 5. Schematic representation of ER stress signaling routes. The purpose of the activation of ER 
stress signaling is to alleviate the effects of ER dysfunction under conditions of varied stress stimuli. Bip is a 
signaling molecule that is sensitive to ER stress. It initiates UPR by activating three ER transmembrane 
sensor proteins. The activation of PERK, IRE1 and ATF6 aims to ease the burden of processing the 
misfolded proteins in ER. This is mediated by activating their corresponding downstream signaling targets. 
JNK and eIF2α are activated by phosphorylation. The activation of the signaling cascade leads to alterations 
in gene transcription. Activation of ER stress response downregulates general protein synthesis and activates 
ERAD genes. Upregulated autophagy contributes to the protein degradation. In the case of severe ER 
malfunction when homeostasis is not achievable the cell is targeted to face apoptosis 
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Dysfunctional intracellular signaling might also be one contributor to ER stress in HD, 
when the release of calcium by inositol 1,4,5 -trisphosphate receptor (IP(3)R) in ER is 
impaired promoting cell death (Higo et al. 2010). The disrupted Ca2+ homeostasis in ER 
stress triggers calpain-mediated cleavage of mHTT to toxic fragments (Gafni and Ellerby 
2002, Gafni et al. 2004).  
 Ubiquitin-specific protease 14 
 Deubiquitinating enzymes in ubiquitin-proteasome-system 
UPS is a critical proteolytic quality control system that is needed in a variety of cellular 
functions. The major function of UPS is to remove soluble, short lived and toxic proteins 
in the cytoplasm and nucleus of the eukaryotic cells. Its role is emphasized in clearance of 
aberrant or misfolded proteins that are associated with numerous human diseases (Finley 
2009). Proteolysis is executed through a multistep mechanism, which includes selective 
recognition of protein substrates, conjugation of substrates with ubiquitin label and 
degradation of conjugated substrates by proteasomes (Ciechanover 2005). The length of 
the ubiquitin moiety on protein substrate determines its interaction on proteasomes, a 
longer chain resulting in stronger interaction (Thrower et al. 2000). Proteolysis via UPS is 
highly energy-dependent and regulated and it is sensitive to various stress factors including 
oxidative stress (Li and Li 2011).  
 
Deubiquitinating enzymes (DUBs) act antagonistically to protein ubiquitination by helping 
to produce free ubiquitin: by cleaving it from ubiquitin-fusion proteins, recycling it from 
ubiquitin-protein conjugates and by editing ubiquitin chains (Anderson et al. 2005, Reyes-
Turcu et al. 2009). Ubiquitin recycling is critical for maintaining a free pool of ubiquitin. If 
ubiquitin molecules are translocated to a proteasomal degradative pore, some of it can 
become degraded (Hanna et al. 2003, Shabek et al. 2009) and some of it can cause 
jamming of the proteasome (Leggett et al. 2002, Hanna et al. 2003, Verma et al. 2002). 
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 Deubiquitinating enzymes 
DUBs regulate various cellular processes from neuronal degeneration to heritable cancer 
diseases (Nijman et al. 2005). DUBs belong to a superfamily of proteases that has over 560 
members and which can be divided into five conserved classes, based on the catalytic 
function of the proteins: cysteine, metallo, aspartatic, serine and threonine proteases 
(Figure 6).  
 
DUBs form a structurally very distinct family of proteins that have overlapping functions 
(Nijman et al. 2005, Reyes-Turcu et al. 2009). Several domains with extensions and 
insertions regulate DUBs specificity to substrates, cellular localization and interaction with 
other proteins (Reyes-Turcu et al. 2009, Komander et al. 2009). Most DUBs regulate only 
a limited number of proteins and pathways, indicating that they operate with a limited 
number of specific target substrates (Nijman et al. 2005, Hu et al. 2005). DUBs are 
produced as inactive precursors that obtain their active conformation when binding to 
ubiquitin, which prevents the spontaneous protease degradation of other substrates (Nijman 
et al. 2005). Like most other proteases, DUB activity is highly regulated to prevent 
accidental cleavage. The regulation of DUBs is executed at many levels, including binding 
to a specific regulatory cofactor, transcriptional level regulation of DUB synthesis and 
proteasomal degradation of mature DUBs (Nijman et al. 2005, Komander et al. 2009).  
 
The USP family is the largest family of DUBs (Nijman et al. 2005, Reyes-Turcu et al. 
2009). The enzymatic activity lies in the thiol group in the conserved cysteine at the active 
site of the enzyme. During catalysis the isopeptide bond between ubiquitin and its substrate 
is hydrolyzed releasing free ubiquitin and the enzyme (Nijman et al. 2005). DUBs 
associating with proteasomes include UCH37 (Lam et al. 1997), Rpn11 (Verma et al. 
2002) and USP14 (Borodovsky et al. 2001, Leggett et al. 2002) which remove the 
polyubiquitin tag from protein-ubiquitin conjugate before translocation to the protein 
degradation system in proteasomes. 
 
 
 
26 
 
 
 
Figure 6. Classification of DUBs and USP14. The superfamily of proteases can be divided into five 
subclasses according to their catalytic activity. Both classes of cysteine and metallo proteases contain DUBs, 
but most of these are cysteine proteases. The cysteineproteases can be further divided into four subclasses 
based on their ubiquitin-protease domains: Machado-Joseph disease proteases (MJD), ovarian tumor (OTU) 
proteases, ubiquitin C-terminal hydrolases (UCH) and ubiquitin-specific proteases (USP). The large USP 
family consists of UCH37, Rnp11 and USP14 that remove ubiquitin tag from protein substrates prior to their 
entry to the proteasomal degradative pore. The catalytic and non-catalytic activities of USP14 are researched 
in this thesis. 
 The known function of USP14 
Ubiquitin-specific protease 14 (USP14), also known as ubiquitin carboxyl-terminal 
hydrolase 14, is one of the best characterized DUBs that is encoded by the genome of 
Homo sapiens. It is encoded by USP14 (18p11.32), which is highly conserved between 
yeast (Ubp6) and mammals and is expressed in a plethora of mammalian tissues. 
Alternative pre-RNA splicing results in two isoforms of USP14, only one of them being a 
fully operative enzyme (Crimmins et al. 2006).   
 
USP14 encodes a protein that consists of 494 amino acids, and its characteristic features 
are a 9 kDa ubiquitin-like (UBL) domain  (Wyndham et al. 1999) at the N-terminus 
followed by a 45 kDa catalytic domain (Hu et al. 2005) (Figure 7). The UBL domain has 
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similar folding pattern as ubiquitin and it is conserved between many eukaryotic species 
(Wyndham et al. 1999). UBL domains were first identified in USP14, and they are now 
known to be present in several members of the USP family of DUBs (Komander et al. 
2009). UPS14 is found in the cytoplasm, and it is one of the DUBs that has been shown to 
be associated via the UBL domain with the base of the 26S proteasome (Borodovsky et al. 
2001) and more specifically with the 19S regulatory particle (Hu et al. 2005). The 
interaction with the 19S proteasome activates the catalytic activity of USP14 in an ATP 
and 20S proteolytic core-independent manner (Hu et al. 2005).  
 
 
A 
UBL domain (1WGG) 
 
Ubiquitin (1UBQ) 
  
 
B 
USP14 catalytic domain in complex with ubiquitin (2AYO) 
 
 
 
Figure 7. Three-dimensional structures of ubiquitin and USP14. A. The 9 kDa UBL domain of USP14 
has a similar folding pattern as ubiquitin, which may reflect a joint evolutionary history. In USP14 the UBL 
domain associates with the 19S proteasome and enhances catalysis. B. The 45 kDa catalytic domain of 
USP14 (blue) bound to ubiquitin aldehyde. The binding of ubiquitin induces a conformational change on the 
blocking surface loops. This enables the access of the binding pocket to the ligand. Images rendered from 
pdb codes (1WGG, 1UBQ & 2AYO) with ChemBio3D Ultra (Perkin Elmer inc.). 
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Studies on the function of Ubp6, the yeast ortholog of USP14, have been instructive during 
the years. Although its specific function remains to be elucidated, it seems that USP14 
serves as a fine regulator to proteolysis. Rnp11 is a stoichiometric unit of the regulatory 
particle of the proteasome and removes the ubiquitin moiety as a block from the base of the 
chain, whereas UCH37 (also known as UCHL5) and USP14 are binding reversibly to the 
proteasomes and can remove single ubiquitin molecules from the chain (Lee et al. 2010) 
(Figure 8). The discrimination between these three DUBs lies in their proteolysis 
promoting activity: Rpn11 promotes protein degradation and USP14 and UCH37 
antagonize it by gradually removing ubiquitin molecules from the tip of the chain in an 
event referred to as “chain-trimming” (Lee et al. 2010). The time that the 
ubiquitin-substrate complex is being modified by chain-trimming can affect the substrate 
degradation and even promote its release from the proteasome. USP14 inhibits 
proteasomes also in a non-catalytic manner (Lee et al. 2010). This non-catalytic inhibition 
slows substrate degradation and may expose individual substrates to chain-trimming more 
extensively. Although it seems that USP14 inhibits proteasomes, it has also been reported 
that it activates proteasomes by opening the 20S gate (Peth et al. 2009). Currently there is 
no crucial understanding concerning how USP14 regulates proteasomal function; this is a 
major challenge for future investigations.  
 
Besides affecting the protein turnover rate, the specific role of USP14 is emphasized in the 
nervous system, especially in the CNS and in synaptic development. Studies involving the 
axJ mutation led to the discovery that USP14 may regulate synaptic transmission and 
neuronal development. Homozygous, spontaneous ataxia mutation (axJ) in Mus musculus 
reduces dramatically the levels of USP14 in both neuronal and non-neuronal tissues, 
resulting in severe tremors in 2–3 weeks of age followed by paralysis of hindlimbs and 
finally death in the weeks 6–10 (D'Amato and Hicks 1965, Wilson et al. 2002). The axJ 
mutation is an intracisternal A-particle insertion, indicating that the mutation represents a 
hypermorphic allele of USP14 (Wilson et al. 2002). Rather than ubiquitin-labeled protein 
aggregates or neuronal loss seen in other neurodegenerative diseases, axJ mice represent 
defects in synaptic transmission in the CNS and the peripheral nervous system leading to 
the conclusion, that USP14 regulates synaptic activity (Wilson et al. 2002). 
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Figure 8. Schematic presentation of USP14 and its deubiquitinating function at the proteasome. 
The proteasome is a multi-subunit protein complex that degrades unneeded or damaged proteins to short 
polypeptide fragments. The major subunits of the proteasome are the 19S regulatory cap particles and in the 
middle the degradative 20S complex. The 19S particle recognizes proteasomal substrates and regulates 
substrate entry to the system. The 20S complex forms an enclosed narrow pore in which proteins are 
translocated and destructed. Proteasomal substrates are targeted to degradation by ubiquitin (ub) molecules. 
USP14 is one of the three known deubiquitinating enzymes that are associated with proteasomes. It consists 
of two subunits: the UBL domain that is associated with the 19S particle of the proteasome and the catalytic 
domain (cat.) that hydrolyzes gradually the isopeptide bond between ubiquitin and proteasome substrate at 
the distal tip of the ubiquitin chain (referred as “chain-trimming”). Chain-trimming may promote substrate 
release from the proteasome and thus it antagonizes substrate degradation.   
 
 
After finding that massive reduction of USP14 causes ataxia, it was showed that the 
viability and motor system function could be restored with neuron-specific expression of 
USP14 (Crimmins et al. 2006). Also notably the ubiquitin monomer levels could be 
restored by USP14 expression which indicates that proteasome dysfunction could 
contribute to the neurological dysfunction in axJ mice (Crimmins et al. 2006). USP14 was 
later found to be essential for synaptic development and function at neuromuscular 
junctions. In contrast to reduced levels of USP14 in axJ mice, loss of USP14 causes 
developmental defects at motor neuron endplates which correlate with observed ubiquitin 
loss (Chen et al. 2009). 
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The significance of ubiquitin homeostasis in synaptic development and function was 
emphasized when it was shown, that neuronally expressed ubiquitin improved the viability 
of axJ mice (Chen et al. 2011). USP14 has also been shown to regulate neurotransmitter 
release through negative influence on the GABAA receptor turnover in CNS (Lappe-Siefke 
et al. 2009).  Ubiquitination of synaptic proteins appears to play an important role in the 
neurotransmitter release and regulating the synaptic vesicle pool size (Bhattacharyya et al. 
2012). This indicates that UPS may be necessary for normal neurotransmission in the adult 
central and peripheral nervous system. USP14 may also regulate synaptic function in a 
deubiquitination-independent mechanism but the evidence for this is still scarce (Walters et 
al. 2013). 
 
A recent study with a novel mutation nmf375 indicates that USP14 is also needed in 
adulthood. This mutation causes aberrant USP14 mRNA splicing in Mus musculus and 
reduces dramatically the amount of USP14, causing depleted ubiquitin levels and 
adult-onset motor endplate disease without depleted ubiquitin levels or neuromuscular 
junction abnormalities (Marshall et al. 2013). It is also postulated, that difference in genetic 
background has a major influence on the phenotypes caused by USP14-deficiency 
(Marshall et al. 2013). 
 IU1 inhibits the deubiquitinating activity of USP14 
If  USP14  can inhibit the degradation of several  proteasome substrates,  it would be 
beneficial  to  find  an  inhibitor to USP14 to enhance  proteasome  function.  
Lee et al. (2010) screened   over   63 000   compounds   for  the  ability  to  inhibit  the 
deubiquitinating  activity of USP14. During the screening they found 
1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone (IU1) (Figure 9). 
The suggestive structure of IU1 is an active-site-directed thiol protease inhibitor and it is 
the first known molecule to selectively inhibit the protease activity of USP14. 
 
Lee et al. (2010) found also that IU1 itself does not affect proteasomal degradation rate and 
that the effect of IU1 to inhibit USP14 was dependent on proteasomes in a way that IU1 
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binds only to the active form of USP14. IU1 produced sharp reduction in the 
chain-trimming rate on ubiquitin chains on proteasomes associated with USP14 and 
accelerated the degradation rate of several substrates that have been associated with 
neurodegenerative diseases (Lee et al. 2010).   
 
 
F N
N
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Figure 9. The chemical structure of IU1. 
 The role of USP14 in Huntington’s disease is unknown 
It is not currently understood how the different functions of USP14 are related (Figure 10). 
The role of USP14 is emphasized in the nervous system. The loss of USP14 dysregulates 
synaptic activity and function, which are related to monomeric ubiquitin levels and 
proteasome dysfunction (Wilson et al. 2002, Crimmins et al. 2006, Chen et al. 2009, Chen 
et al. 2011). Although the specific role of USP14 remains unclear, it has been shown that it 
antagonizes proteolysis in a non-catalytic manner and by ubiquitin chain-trimming (Lee et 
al. 2010). However, it has been reported that it activates proteasomes by opening the 20S 
gate (Peth et al. 2009). The activity of USP14 is also involved in ER stress signaling in a 
catalytic and non-catalytic manner (Nagai et al. 2009, Jin et al. 2012).  
 
The effect of catalytic inhibition of USP14 with IU1 has not been previously investigated 
in neuronal cells with the mHTT model. Lee et al. (2010) have shown in mouse embryonic 
fibroblast (MEF) cells and HEK293 cells that USP14 inhibits the turnover of exogenously 
expressed proteins ataxin-3, TDP-43 and tau, which are all associated with 
neurodegeneration (Todi et al. 2007, Kwong et al. 2008, Spires-Jones et al. 2009, Lee et al. 
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2010). They also showed that IU1 increased strongly the degradation of these proteins in 
MEF cells. However, it was later shown in vivo that loss of USP14 did not affect the levels 
of endogenic tau or ataxin-3, and thus it was suggested that the expression of these proteins 
is not controlled by USP14 in neurons (Jin et al. 2012). Although only little is known about 
the function of IU1 to date, this molecule sets an interesting direction for future studies of 
the effect of USP14 in neurodegeneration and possibly for development of therapy and 
treatment. 
 
 
 
 
Figure 10. Summary of the current known functions of USP14. One of the important functions of the 
deubiquitinating activity of USP14 is the maintenance of the cellular free ubiquitin pool. USP14 is associated 
with neuronal development and dysfunction, which in turn is suggested to be associated with ubiquitin 
homeostasis. USP14 serves as a fine regulator of the proteolysis, as it antagonizes proteolysis by 
chain-trimming and by a non-catalytic mechanism. It has also been reported that USP14 activates the 
proteasomal 20S gate. The relation between these functions is not known. USP14 also inhibits ER stress in 
both catalytic and non-catalytic manner 
 
 
The function of USP14 and mechanisms of HD pathogenesis (Figure 2) are partially 
overlapping. However, it has not been investigated how the catalytic and non-catalytic 
activities of USP14 contribute to the disease.   
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2 AIMS OF THE STUDY 
The general aim of this study was to characterize the molecular mechanisms of USP14 
function both in wild-type cells and in a HD cell model. 
 
The specific aims were to investigate the role of USP14 in 
1. Antioxidant expression 
2. ER stress 
3. Autophagy 
4. mHTT aggregate dynamics 
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3 MATERIALS AND METHODS 
 Cell culture 
PC6.3 is an immortalized neuronal cell line derived from pheochromocytoma PC12 cells 
(Pittman et al. 1993). This model can be applied to study biochemical and molecular events 
involving neuronal programmed cell death occurring in neuronal development or diseases.  
 
PC6.3 cells were cultured on Nunc dishes in RPMI 1640 medium (Lonza) supplemented 
with 100 mM penicillin-streptomycin (Gibco), 200 mM L-glutamine 200mM (Lonza), 
10% horse serum and 5% fetal calf serum (Invitrogen). 
 Transfections 
PC6.3 cells were transfected with expression vectors using Transfectin Lipid Reagent 
(BioRad) following the instructions provided by the vendor. A typical transfection protocol 
is listed in Table 4. Fresh media containing serum was added 2 h after transfection and the 
cells were allowed to grow 22 to 44 h before they were lysed.  
 
 
Table 4. Typical transfection protocol. 
PLATE TYPE 6-well 24-well 
CELL COUNT 800 000 100 000 
TRANSFECTIN 7 µl 5 µl 
DNA 9 µg 1 µg 
PLATING VOLUME 1ml + 2 ml 500 µl + 200 µl 
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In some experiments USP14 inhibitor IU1 100 µM (Sigma) was added 2 h after 
transfection and controls were treated with DMSO (AppliChem). In addition, positive 
controls of ER stress, 2 mM thapsigargin (Sigma) and 1 µg/µl tunicamycin (Sigma) were 
added 2 h after transfection. The positive control of autophagy, 20 ng/ml rapamycin 
(Calbiochem), was also added 2 h post-transfection in some experiments.  
 Plasmids 
Huntingtin plasmids 
 
HTT plasmid constructs were a gift from Dr. Hasholt2. The HTT exon 1 cloning vectors 
were constructed from leucocytes obtained from Huntington’s disease patients and normal 
individuals (Nellemann et al. 2000). Genomic DNA was extracted and amplified with 
PCR. The PCR primers were designed in a way that they also amplified the flanking 
sequence downstream of the 5’ end in order to make the gene fully functional and added a 
TAA stop codon to the 3’ end of the final PCR product. The PCR primers also contained 
sequences for restriction enzyme recognition sites for subsequent cloning into the 
pBluescript SK(+) plasmid. The 18Q (encodes 18 glutamines) and 120Q (encodes 120 
glutamines) constructs were created by releasing the initial HD segment from the cloning 
vector and inserting them into the pEGFPN1 expression vector (Clontech) (Hasholt et al. 
2003). The 120Q construct was amplified in PCR prior to the cloning. This plasmid 
encodes an enhanced fluorescent green protein (EGFP) that was used to detect the protein 
product. The transfection time of 18Q and 120Q was 24 h.  
 
 
 
 
 
 
                                                 
2 Section of Neurogenetics, Institute of Medical Biochemistry and Genetics, University of Copenhagen, 
Denmark 
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Full-length huntingtin plasmids 
 
The full-length 17Q and 75Q HTT protein expression vectors were a gift from Dr. 
Saudou3. The HTT genes were cloned in expression vector pCMV-Neo-Bam from 
SV-40-HD15 and SV-40-HD73 (17Q and 75Q respectively) (Saudou et al. 1998).  
 
USP14 plasmid 
 
USP14 plasmid was a gift from Dr. Yihong Ye4. The plasmid pRK-FLAG-Usp14 was 
constructed by cloning the human Usp14 cDNA in the Not1 and Sal1 sites in the pRK-Flag 
vector (Wang et al. 2006).  
 
LC3 plasmid and GADD34 plasmid 
 
LC3 and GADD34 plasmids were obtained from Addgene.  
 
Control plasmid 
 
The EGFP expression plasmid (Clontech) was used as a control.  
 Western blot 
Cells were washed once with ice-cold Phosphate buffered saline (PBS) and lysed in 
radioimmunoprecipitation assay buffer (RIPA) containing 50 mM Tris-HCl (pH 7.4), 1% 
NP-40 (Fluka), 0.25% sodium-deoxycholate (Sigma), 150 mM NaCl, 1 mM EDTA 
(Sigma) and 1% sodium dodecyl sulfate (SDS) with added  phosphatase  inhibitor 
(Thermo Scientific) and protease inhibitor cocktails (Roche). A sonicator was used to tear 
down the cells and viscose DNA, and homogenize the extract. Protein concentration was 
                                                 
3 Division of Neuroscience, Department of Neurology, Children’s Hospital, Boston, Massachusetts 02115 
4 Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, 
National Institutes of Health, Bethesda, MD 20892 
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measured with Pierce BCA Protein Assay (Thermo Scientific) and samples were stored 
at -70°C.  
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels were 
prepared according to the molecular weight of separated proteins (Table 5). Equal amounts 
of protein samples were heated at 100°C for 5 minutes with 4× Laemmeli sample buffer in 
order to denature protein structures. Samples were loaded onto SDS-PAGE gel with a 
molecular weight marker (PageRuler Plus Prestained Protein Ladder, 10 to 250 kDa). After 
the gel run proteins were transferred on ice onto Hybond-C Extra nitrocellulose filters 
(Amersham Biosciences, Helsinki, Finland). Bio-Rad electroblotting systems were used in 
both separating and transferring proteins.  
 
 
Table 5. Typical gel percentages and blotting times depending on the molecular 
weight of proteins. 
PROTEIN SIZE (kDa) GEL DENSITY (%) BLOTTING MINUTES 
12 15 25 
16–23 15 30 
27–42 10 45 
46–60 10 60 
 
 
Nitrocellulose filters were washed five minutes with Tris-buffered saline (TBS) containing 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, followed by 1 h blocking at room temperature in 
5% skimmed milk or 5% bovine serum albumin (BSA) (Sigma) that were diluted in TBS. 
Filters were then incubated on the shaker overnight at +4°C with the primary antibodies 
(Table 6). Antibodies were then washed from the filters three times five minutes with 
TBS+0.1% Tween-20 at room temperature to minimize the background. Filters were 
incubated with secondary antibodies (Table 7) for 1–2 h at room temperature and rewashed 
as described earlier.  
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Table 6. Primary antibodies.  
TARGET SPECIES SIZE (kDa) DILUTION MANUFACTURER CODE 
Actin Rabbit 42 1:10 000 Sigma-Aldrich A2066 
eIF2α Rabbit 38 1:4000 Cell Signaling 9722 
GFP Mouse 27 1:6000 Roche Applied Science 11 814 460 001 
JNK Rabbit 46 & 54 1:4000 Cell Signaling 9252 
p-eIF2α Rabbit 38 1:3000 Cell Signaling 3597 
p-JNK Rabbit 46 & 54 1:3000 Cell Signaling 9251 
SOD1 Rabbit 16 1:10 000 Santa Cruz Biotechnology sc-11407 
SOD2 Mouse 23 1:6000 AbFrontier LF-MA0030 
Trx2 Rabbit 12 1:800 AbFrontier LF-PA0012 
USP14 Mouse 60 1:7000 Abnova H00009097-A01 
 
 
Table 7. Secondary antibodies. Antibodies from Rockland Immunochemicals are conjugated with 
fluorophores and from Jackson Immunoresearch with horseradish peroxidase. 
TARGET SPECIES DILUTION MANUFACTURER CODE 
IRDye 700DX Rabbit 1:5000 Rockland Immunochemicals 611-730-127 
IRDye 800CW Rabbit 1:5000 Rockland Immunochemicals 611-731-127 
IRDye 800 Mouse 1:5000 Rockland Immunochemicals 610-732-127 
Peroxidase-AffiniPure Mouse 1:2500 Jackson Immunoresearch 115-035-044 
Peroxidase-AffiniPure Rabbit 1:2500 Jackson Immunoresearch 111-035-003 
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Antibodies conjugated with fluorophores were detected by Oddyssey CLx infrared imager. 
In some experiments secondary antibodies were conjugated with horseradish peroxidase 
and detected with enhanced chemiluminescent method with Super Signal West Pico 
Chemiluminescent substrate (Thermo Scientific) and with Kodak BioMax MR film and 
Kodak reagents.  
 Solubility assay 
Solubility assay was used to separate soluble and insoluble proteins and separate and detect 
the insoluble fraction with western blot. PC6.3 cells were washed once with ice-cold PBS 
and lysed in solubility buffer containing 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 3 mM 
EGTA (Sigma) and 0.5% Triton X-100 (Sigma) with added  phosphatase  inhibitor 
(Thermo Scientific) and protease inhibitor cocktails (Roche). Samples were kept on ice for 
10 minutes and centrifuged 14000 rpm at 4°C for 10 minutes. Insoluble fraction (the pellet) 
was sonicated with added 1× Laemmeli sample buffer and boiled at 100°C. Samples were 
loaded on 10% SDS-PAGE gel with extra-long stacking gel. Both stacking and separating 
gels were blotted in order to detect the large molecular weight insoluble HTT aggregates. 
 Microscopy analysis and cell counting 
The coverslips in a 24-well plate were coated with 0.5 mg/ml poly-DL-ornitine 
hydrobromide (Sigma) diluted in PBS for 1 h at room temperature and with 3 µl of 1 
mg/ml laminin (Sigma) diluted in PBS. Coverslips were washed three times with PBS after 
each of the coating agents were supplemented on the well. After the coating PC6.3 cells 
(100 000 cells per well) were plated on the coverslips and transfected as described earlier. 
The media was removed and cells were rinsed with PBS, following of 20 minutes of 
fixation at room temperature with 4% paraformaldehyde (PFA) (Sigma) diluted in PBS. In 
the end cells were washed three times with PBS. The plates were wrapped in parafilm and 
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stored at 4°C. For microscopic inspection the fixed coverslips were mounted on the 
microscope slides with Mowiol (Sigma).  
 
Mutant HTT aggregate analysis 
 
Cells that were transfected with expression vectors fused to fluorescence protein were 
visualized and analyzed by Leica Microsystems (DM4500 B) fluorescent microscope using 
Leica Application Suite (version 2.3.1 R1). In each experiment only those cells that had the 
green fluorescence marker were counted. 
 
Autophagy analysis 
 
To detect the ongoing autophagy above baseline the LC3-RFP marker was used. LC3 has 
two isoforms, I and II (Kabeya et al. 2000). The amount of isoform II, converted from 
isoform I, is associated with autophagosome membranes and represents ongoing 
autophagy.  
 
The red fluorescent protein (RFP) marker was verified from a cell by fluorescence 
microscopy. If a cell had a RFP marker, it was considered to have a successful transfection 
of the LC3 plasmid. In autophagy analysis a cell was assumed to experience autophagy 
when more than five autophagosomal vesicles were countable during microscopy 
(Hyrskyluoto et al. 2012).  
 Quantifications  
The western blot films were scanned and quantified with ImageJ software (NIH), version 
1.47. β-actin was used as a loading control for every protein in a way that the total amount 
of protein sample was proportioned to the control.  
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 Statistics 
Western blot analysis was performed with an antibody only once with given a cell lysate, 
in order to obtain statistically independent samples. Statistical analyses were performed 
using one-way ANOVA with 3 groups, and two-way Student’s t-test with two groups. 
Microsoft Excel (2010 and 2013) was used to calculate the values. For all experiments 
p <0.05 was considered significant. In experiments when n= >1 the values were expressed 
as means with ±SD. 
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4 RESULTS 
 Testing the model system 
I started my research by confirming the previously described model by Reijonen et al. 
(2008). I transfected PC6.3 cells with plasmids harbouring fusion protein constructs 
containing N-terminal mHTT plasmid with 18 or 120 residues of CAG fused to GFP. The 
construct with 18 CAG residues represents the normal non-mutated protein. As shown in 
Figure 11A, the expression of mHTT plasmid containing disease-causing 120 polyQ repeat 
induces prominent aggregation of the protein, which is not observed in GFP-transfected 
control cells. The production of the HTT-GFP fusion proteins expressing 18 and 120 
polyQ repeats was verified by western blot (Figure 11B). In the following experiments 
when the expression of mHTT was examined, it was confirmed that the cell lysates were 
transfected with the mHTT plasmid, which was seen as positive GFP staining with the 
corresponding antibody. 
 
To study the effects of USP14 in the PC6.3 cell model for HD, I overexpressed the protein 
or inhibited its catalytic activity by IU1. Before these experiments I investigated the effect 
of mHTT on the expression of USP14. I transfected PC6.3 cells with both 18Q and 120Q 
N-terminal HTT plasmid constructs and immunoblotted the cell lysates against USP14 
antibody (Figure 12A). The quantification of the immunoblots shows that the expression of 
USP14 is not significantly affected by transfection with 18Q or 120Q repeat-containing 
HTT construct (Figure 12B). The data were statistically tested with single factor ANOVA, 
which indicated that there was no statistical difference between the three groups. In the 
following experiments with USP14 it is postulated that the expression level of the protein 
is not dependent on the N-terminal HTT expression. 
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Figure 11. Expression of N-terminal mHTT proteins induces protein aggregation in PC6.3 cells. PC6.3 
cells were transfected as described in Materials and Methods with plasmids encoding fusion protein 
constructs containing 18 or 120 CAG expansions at exon 1 in N-terminal HTT fused to GFP. A. PC6.3 cells 
were transfected 24 h with GFP and 120Q HTT-fusion protein linked to GFP. Fluorescence microscopy 
shows presence of mHTT protein aggregates (green fluorescence). Note the aggregation of mHTT in 
120Q-transfected cell. Scale bar, 10 µm. B. Immunoblot using antibody against GFP, β-actin was used as a 
control. Note the expression of different HTT-fusion proteins. C, control. 18Q or 120Q, 18 or 120 glutamine 
repeats, respectively. 
 
I wanted to study the effect of IU1 treatment since it has not been investigated previously 
in this model system. I transfected the PC6.3 cells with the GFP-containing control 
plasmid, and treated the cells with DMSO or IU1. Immunoblotting was done against 
β-actin that is used as a general measure of protein expression level. Quantification and the 
statistical analyses of 23 immunoblots showed with p=0.6 that β-actin expression in the 
PC6.3 cells was independent of the IU1 treatment (Figure 12C). Since IU1 is diluted in 
DMSO, the control cell group in the following experiments is always exposed to it when 
IU1 has been studied. 
 
 
 
 
 
 
44 
 
 
Figure 12. The expression of USP14 and β-actin are not affected by transfection of N-terminal 
huntingtin construct or treatment with IU1. PC6.3 cells were transfected for 24 h with N-terminal 
HTT-fusion proteins containing 18 or 120 repetitions of CAG fused to GFP. Quantifications were performed 
by calculating the relative level of protein expression proportional to β-actin expression. In the plot the 
control level expression is normalized to 1. Statistical analyses were performed as described in Materials and 
Methods. A. Immunodetection was done using an antibody against USP14. β-actin was used as a control. 
B. Quantification show that the expression of USP14 is not significantly affected by transfection with 18Q or 
120Q N-terminal HTT plasmids. Values are mean ±SD, n=3. ANOVA: F(2,6)=0.003, p=0.99. 
C. Quantification showing that the expression level of the β-actin in cells that have been transfected with the 
GFP plasmid is not significantly affected by IU1 treatment. Values are mean ±SD. N=23, p=0.60.  
 IU1 decreases the expression of superoxide dismutases 1 and 2 
First I confirmed the results obtained by Reijonen et al. (2010) with my cell lysates. The 
expression of SOD1, SOD2, and Trx2 was measured from PC6.3 cells that were 24 h 
earlier transfected with 120Q mHTT-expressing vector (Figure 13A & C). Then I treated 
the cells with IU1 and immunodetected the proteins with the corresponding antibodies 
(Figure 13B). The quantification of the immunoblots show that catalytic inhibition of 
USP14 decreases the expression of SOD1 and SOD2, although there is a large variance 
(Figure 13C). The amount of Trx2 is increased in the control and 120Q cells compared 
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with DMSO-treated cells. Student’s t-test was performed for SOD1, in which no 
significant differences between the two groups were detected. For SOD2, single factor 
ANOVA indicated statistical significance between DMSO and IU1 treatment. However, 
probably due to a small sampling size, examination by Student’s t-test showed only a trend 
in regulation and no statistical significance. 
 
 
Figure 13. IU1 decreases SOD1 and SOD2 levels in the control cells, and in cells that are transfected 
with mHTT plasmids (120Q). A–B. Immunoblots showing that SOD1, SOD2 and Trx2 expression is 
downregulated when cells are transfected 24 h with 120Q-containing plasmid. β-actin was used as a control. 
C. Quantifications of the immunoblots showing that the levels of antioxidants decrease when transfected with 
120Q. IU1 treatment decreases the control level and 120Q expression of SOD1 and SOD2, and the level of 
Trx2 increases in both groups. For SOD1, SOD2 and Trx2 n= 2, 3 and 1 respectively.  Values are mean ±SD. 
For SOD1: C vs C+IU1 p=0.26, 120Q vs 120Q+IU1 p=0.37. In IU1 treated group C vs 120Q p= 0.12. For 
SOD2: ANOVA: F(3,8)=5.71, p=0.022. C vs C+IU1 p=0.053, 120Q vs 120Q+IU1 p=0.83. In IU1 treated 
group C vs 120Q p=0.28. 
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 IU1 has complex effects on ER stress 
I started my experiments by confirming the results obtained by Reijonen et al. (2008, 2010) 
with my cell lysates. (Figure 14A & D). The signaling protein is considered to be activated 
via phosphorylation. In some of my experiments I included thapsigargin and tunicamycin 
as positive controls to induce ER stress in the cell (Figure 14B). The effect of IU1 was 
investigated by western blot analysis of the amounts of the PERK and IRE1 pathway 
proteins that had been studied by Reijonen et al. (Figure 14C). Quantification of the 
immunoblots (Figure 14A) shows, that the cell lysates contained increased levels of ER 
stress proteins, the effect being prominent for p-eIF2α and minor for p-JNK (Figure 14D). 
The quantified data from IU1 western blot revealed that catalytic inhibition of USP14 
resulted in reduced expression of ER stress proteins p-eIF2α and p-JNK (Figure 14E). 
Comparison of the quantified data reveals the complex effects of IU1 treatment 
(Figure 14F). At the basal level it appears that IU1 increases ER stress, while in the HD 
model the catalytic inhibition of USP14 decreases ER stress.  
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Figure 14. IU1 increases the phosphorylation of ER stress proteins at the basal level and decreases it in 
the 18Q- and 120Q-expressing cells. A. Immunoblots confirming previously obtained data of ER stress and 
showing that mHTT expression increases phosphorylation of signaling proteins. B. Immunoblots showing 
that thapsigargin (Th) and tunicamycin (Tu) stimulates ER stress. C. Immunoblots presenting that treatment 
of IU1 decreases ER stress in cells expressing 18Q and 120Q. D–E. Quantifications were performed by 
calculating the relative levels of the protein expression: the expression of phosphorylated protein is 
proportionated to the inactive form of protein and to β-actin. For all proteins n=1. D. Quantification of the 
immunoblots (A) shows that 120Q transfection increases the expression of ER stress proteins p-eIF2α and 
p-JNK. E. Quantification of immunoblots (C) shows that IU1 decreases the expression of p-eIF2α and 
p-JNK. Note the differences between polyQ stretch compared to the expression of ER stress proteins. 
F. Comparison of the quantified data reveals the different effects of IU1 on ER stress at the basal level and in 
HD model.  
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 IU1 increases autophagy in 120Q expressing cells 
I transfected the PC6.3 cells for 24 h with the plasmid containing the construct with 120 
repetitive units of CAG together with the LC3 plasmid in order to detect the ongoing 
autophagy (Figure 15A). Some cells were transfected with LC3-RFP and GFP constructs 
and treated with rapamycin. These cells were considered as positive controls for 
autophagy. Some of the cells were transfected with USP14 for 24 h and some got IU1 
treatment for 22 h. The N-terminal HTT expression was compared to control cells that had 
only the GFP-containing plasmid.  
 
Cells that were selected for autophagy analysis were confirmed to express mHTT 
aggregates. The ongoing autophagy is visualized in red fluorescence vesicles and more 
than five vesicles were considered as positive (Hyrskyluoto et al. 2012). The visual mHTT 
aggregates were heterogeneous but clearly differentiated from the non-aggregate bearing 
cells by condensation and enhanced fluorescence.  
 
The visual observation of the cells revealed that the USP14 overexpression and IU1 
treatment did not affect the cell morphology or the amount of cells. The counting and 
quantification confirm the previous data from the PC6.3 HD cell model, in which mHTT 
induces autophagy (Figure 15B) (Hyrskyluoto et al. 2012). USP14 overexpression inhibits 
autophagy in 120Q-transfected cells while IU1 strongly upregulates autophagy at the 
control level and in 120Q-transfected cells (Figure 15B).  
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Figure 15. Inhibition of the catalytic activity of USP14 enhances autophagy at the control and 120Q 
level, while USP14 overexpression inhibits autophagy in 120Q transfected cells. A. Cells were 
transfected 24 h with GFP (green fluorescence) or N-terminal HTT construct containing 120 CAG units and 
GFP together with autophagy marker LC3-RFP plasmid (red fluorescence). Some of the cells were 
transfected with USP14 and some were treated with IU1. Rapamycin was used as a positive control of 
autophagy. Note the ongoing autophagy in autophagosomic vesicles in 120Q and rapamycin-treated cells. 
Scale bar, 10 µm. B. The amount of green and red fluorescence-containing control cells, and aggregates 
producing green fluorescence cells containing more than five autophagosomal vacuoles per cross section, 
were counted and quantified. N= ~97 cells. 
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 GADD34 increases USP14 expression 
The PC6.3 cells were transfected with 18Q and 120Q plasmid constructs and with 
full-length 17Q and 75Q plasmids together with GADD34 plasmid (Figure 16A & C). The 
amount of the USP14 protein was assessed by western blot 24 h or 48 h after transfection. 
The quantification of the immunoblots revealed that the expression level of USP14 was 
indeed moderately affected by GADD34 overexpression and it was found to be increased 
in all transfected groups (Figure 16B & D). After 24 h of the transfection, the level of 
GADD34 overexpression became most evident in 18Q-transfected cells, while the effect of 
the protein was minor and similar in the control and 120Q groups (Figure 16B). When cells 
were transfected with the full-length HTT, interestingly the greatest difference was in the 
control group, and only marginal with 75Q plasmid (Figure 16D). Also the expression 
level of USP14 increased with the repeat length of CAG. 
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Figure 16. GADD34 overexpression increases USP14 expression. A–B. Immunoblot and quantification 
showing that overexpression of GADD34 increases USP14 expression at the 24 h timepoint in 18Q- and 
120Q-transfected PC6.3 cells. C–D. Immunoblot and quantification presenting the data from the 48 h 
timepoint: GADD34 overexpression increases the expression of USP14. The level of the control plasmid was 
normalized to 1. N=1 for both experiments. 
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 USP14 decreases mHTT aggregates  
In my previous investigations I have studied the USP14 contribution to different HD 
pathogenesis routes. In this experiment I wanted to investigate mHTT expression itself and 
the contribution of USP14 to the aggregate dynamics. I transfected the PC6.3 cells 24 h 
with 18Q-GFP and 120Q-GFP fusion protein plasmids. Some cells were transfected with 
USP14 or treated with IU1. The visual observation with fluorescence microscopy revealed 
that USP14 overexpression and IU1 treatment did not affect the cell count or morphology. 
Aggregates were prominent and more defined in 120Q cells compared with 18Q cells 
(Figure 17A). Calculating the aggregate containing cells and quantifying the data revealed 
that USP14 overexpression decreased the insoluble aggregate load of PC6.3 cells 
(Figure 17B).  The effect was evident even in an 18Q-transfected cells.  
 
I further wanted to investigate the mechanism by which USP14 decreases the aggregate 
amount. To examine if the effect was dependent on catalytic activity of USP14, I 
transfected PC6.3 cells with N-terminal HTT plasmids, containing 18 or 120 repetitive 
units of CAG fused to GFP and treated the cells with IU1. Quantification of the cells 
showed that the IU1 treatment had only a marginal effect on the cell count (Figure 17C). 
The effect of IU1 on aggregates was confirmed with insoluble western blot assay, in which 
the insoluble GFP-fusion protein fraction is visualized on the top of the blot (Figure 17D). 
The assay supports the data from cell count and verifies that IU1 does not affect the mHTT 
aggregate dynamics.  
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Figure 17. USP14 overexpression decreases mHTT aggregates while inhibition of USP14 does not 
affect the amount of aggregates. A. Typical presentation of aggregates from 18Q- and 120Q-transfected 
cells. Cells were transfected 24 h with fusion constructs of GFP and N-terminal HTT with 18 and 120 CAG 
units. Scale bar, 10 µm. B. Quantification of cell counting shows that overexpression of USP14 decreases the 
amount of mHTT aggregates in 18Q- and 120Q-transfected PC6.3 cells. N= ~830 cells per group. C. 
Quantification of cell counting presenting that the treatment with IU1 has only a marginal effect on the cell 
count. N= ~774 cells per group. D. Insolubility assay. Immunoblotting was performed as described in 
Materials and Methods separating the insoluble fraction of protein extract on the top of the membrane. Note 
the expression of different HTT-fusion proteins and protein aggregates on the top of the immunoblot. C, 
control. 
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5 DISCUSSION 
 USP14 reduces mHTT aggregates in UPS dependent manner 
The accumulation of mHTT aggregates has been observed in several cell and animal 
models, and also in human post-mortem brain tissue samples (Zoghbi and Orr 2000, Ross 
and Tabrizi 2011). The plasmid that I used to simulate Huntington’s disease in the cell has 
been previously expressed successfully in different cell types, including NT2-N and 
cortical neurons (Hasholt et al. 2003, Wareski et al. 2009, Cagalinec et al. 2013). It has 
been shown previously that 120Q transfection induces heavy aggregation of the protein in 
this model system (Reijonen et al. 2008). 
 
Since USP14 has a protective role in neuronal cells, the initial hypothesis for this 
experiment was that USP14 overexpression upregulates the clearance of mHTT insoluble 
aggregates (Crimmins et al. 2006, Chen et al. 2009). In this study I show that the 
expression of USP14 reduces the amount of insoluble mHTT aggregates. This effect is 
likely to be dependent on the catalytic activity of USP14, since the inhibition of the activity 
restored the aggregate amount to normal level measured both by cell counting and with the 
insoluble western blot assay. Since the experiment was done only once, I could not analyze 
the data statistically. However, the sample size was large enough to add credibility and 
value to the data. 
 
It is interesting that not inhibition but overexpression of USP14 seems to be protective 
against mHTT aggregates in neuronal-like PC6.3 cells. The effect of USP14 has not been 
investigated in the neuronal model of HD and it might be that in PC6.3 cells the 
proteasome-activating role of the enzyme has a relevant part in overall protein turnover. It 
is plausible that the regulation of tau and ataxin-3 degradation pathways differs from the 
ones that mHTT follows, and the results observed previously with IU1 cannot be 
extrapolated dircetly to mHTT dynamics (Lee et al. 2010).  
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The role of USP14 in autophagic clearance of mHTT has not previously been investigated, 
although it has been shown that the impairment of UPS has yet an unknown role in mHTT 
accumulation (Imarisio et al. 2008, Li and Li 2011). When IU1 is administrated to the 
cells, the protein turnover rate of ataxin-3, TDP-43 and tau is increased in an autophagy 
independent manner (Lee et al. 2010). However, it is not known how mHTT is cleared: via 
autophagy, proteasomes or both mechanisms together. In the PC6.3 cell model it has 
previously been shown that the number of LC3 positive vesicles increases as the mHTT 
polyQ count increases (Hyrskyluoto et al. 2012). The initial hypothesis for the experiments 
with USP14 was based on the general assumption that USP14 is a protective molecule in 
the nervous system but it has no effect on autophagy. 
 
I show here that USP14 inhibits autophagy in a catalytic domain-dependent manner as 
USP14 overexpression inhibits autophagy and IU1 induces it. However, the data should be 
confirmed by studies with several cell lysates in order to gain statistical value to the data 
presented here. Nevertheless the study serves as a guideline for further studies of USP14 
function in autophagy. This finding suggests that USP14 mediates the clearance of mHTT 
aggregates in an UPS-dependent manner. However, one must keep in mind that although 
UPS is the most important selective degradative pathway in the cell with autophagy, also 
the lysosomal pathway could be affected (Ciechanover 2005). My finding supports the 
suggestion that UPS and autophagy are coupled events in HD. Based on my results it 
indeed seems that autophagy operates as a backup mechanism in the clearance of mHTT.  
 
One possible explanation for the increased autophagy at both basal level and in IU1-treated 
mHTT-expressing cells may be the involvement of ubiquitin homeostasis. USP14 is known 
to be an essential enzyme for ubiquitin recycling (Crimmins et al. 2006). As cells are 
exposed to IU1, it antagonizes the ubiquitin release and decreases the free level of the 
molecule (Lee et al. 2010). It may be possible, that when proteins are degraded fast and 
USP14 is not able to separate the ubiquitin from its substrate, ubiquitin becomes degraded 
as well and the proteasome targets are decreased. This may shift the degradation processes 
toward autophagy, since it is suggested that autophagy is a backup mechanism for UPS 
(Levine and Kroemer 2008, Li and Li 2011). The homeostasis of ubiquitin may also 
contribute to autophagy, as it is suggested that autophagy can operate also in a selective 
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manner, and it is not just a bulk degradation mechanism (Klionsky 2007). It is plausible 
that USP14 provides ubiquitin substrates not just for UPS but for autophagy as well, since 
the selection of the substrates from the cytoplasm is postulated to operate via ubiquitin 
targeting (Korolchuk et al. 2010). However, this process is currently poorly understood. 
 
Apart from being bulk degradative machinery, autophagy is considered also a cell death 
mechanism. It is not currently known what indicates the switch between protective and 
death prone autophagy (Levine and Kroemer 2008). The LC3 vesicles are considered as a 
protective mechanism for a cell to try to degrade matter, but what determines when this 
massive vacuolization reaches its saturation point and becomes deleterious can only be 
speculated. It may be that in the early phase of the pathogenesis of HD autophagy is 
cytoprotective, but as the disease advances autophagy drives the cell to its death 
(Ravikumar et al. 2002). The role of USP14 as an autophagy inhibitor in the HD model 
verifies its protective role if the IU1-activated autophagy is leading to cell death.  
 The catalytic activity of USP14 downregulates ER stress via 
GADD34 in non-stressed conditions  
Catalytic inhibition of USP14 may lead to ER stress 
 
Nagai et al. (2009) have shown that in non-stressed conditions USP14 inhibits ER stress in 
a catalytic-free mechanism by binding to IRE1α, which is one of the two homologs of 
mammalian IRE1 (Tirasophon et al. 1998, Wang et al. 1998). Nagai et al. (2009) also 
showed that overexpression of USP14 inhibits ERAD, while siRNA inhibition of USP14 
activates ERAD, demonstrating that USP14 is involved in the UPR signaling network and 
it serves as an inhibitor of ERAD under non-stressed conditions. It has also been shown in 
vivo that loss of USP14 activates JNK (Jin et al. 2012). Thus, it seems that USP14 is a 
protective protein preventing the leak of ER luminal proteins to the cytosol and cell death 
via the IRE1 pathway.  
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Based on the previous evidence, the hypothesis of this thesis was that IU1 has no effect on 
ER stress signaling molecules. However, the data from my experiments suggest that the 
catalytic inhibition may activate ER stress. As the sample size is only one in all of the 
experiments, the necessary statistical analyses could not be performed. Nevertheless the 
data clearly show the tendency of the regulation, because all the ER stress-associated 
pathways are coherently reacting to the treatment. The catalytic inhibition of USP14 
upregulates the IRE1 pathway by phosphorylation of JNK, and the PERK route by 
phosphorylation of eIF2α. Based on this evidence it may be plausible, that USP14 has also 
a catalytic-site dependent role in ER stress signaling, and the deubiquitinating activity is 
protective in non-stressed conditions. The previous studies have been carried out with 
non-neuronal cells, thus regulation may follow a different pattern in PC6.3 cells. Based on 
the previous data and the results in this thesis it is possible, that both non-enzymatic and 
chain-trimming activities of USP14 cause ER stress (Nagai et al. 2009, Jin et al. 2012).  ER 
stress and USP14 has been investigated previously only in IRE1 pathway proteins (Nagai 
et al. 2009, Jin et al. 2012). In my studies I was able to connect the chain-trimming activity 
of USP14 to both IRE1 and PERK pathways. However, this data needs to be confirmed. 
 
USP14 prevents ER stress signaling via GADD34 
 
The role of p-eIF2α upon ER stress is to help in recovery from the stress by 
downregulating general protein synthesis, initiating protective autophagy and protecting 
from oxidative stress (Boyce and Yuan 2006, Hetz 2012, Rutkowski and Kaufman 2004). 
GADD34 has also an important role in UPR and in restoration of the general translation 
during cell injury, as it regulates the conversion of p-eIF2α to eIF2α (Novoa et al. 2001, 
Novoa et al. 2003). However, the role of GADD34 in ER stress regulation remains largely 
unknown. 
 
It has been previously shown that GADD34 upregulates autophagy in mHTT-expressing 
PC6.3 cells at the 24 h timepoint after transfection; however this effect was reversed at the 
48 h timepoint (Hyrskyluoto et al. 2012). Since I showed that USP14 downregulates 
autophagy in 120Q-expressing cells, it became interesting to investigate if USP14 regulates 
autophagy via GADD34. The hypothesis was that GADD34 overexpression would 
 
 
58 
 
decrease USP14 expression at the 24 h timepoint, and 48 h after transfection the result 
would be inversed. 
 
My results demonstrate that at 24 h and 48 h timepoints GADD34 overexpression 
increases the expression of USP14, which suggests that the signaling routes of GADD34 
and USP14 are interconnected. However, this data needs to be confirmed statistically. 
Based on the findings in this thesis it may be plausible, that in addition to the IRE1 
pathway, USP14 operates in non-stressed conditions via the PERK route, thus preventing 
ER stress (Nagai et al. 2009, Jin et al. 2012). This hypothesis is supported by the 
preliminary data, which indicate that catalytic inhibition of USP14 stimulates ER stress via 
the conversion of p-eIF2α to eIF2α (Figure 18). 
 
 
GADD34 p-eIF2
eIF2 IU1USP14  
 
Figure 18. The results suggest, that the catalytic activity of USP14 might be involved in the prevention of 
ER stress in a healthy cell via the GADD34 signaling route, as IU1 upregulates p-eIF2α, and GADD34 
operates in the dephosphorylating feedback loop converting p-eIF2α to eIF2α. Phosphorylated eIF2α induces 
ER stress. 
 USP14 regulates autophagy and ER stress in HD 
The signaling routes between USP14 and GADD34 in HD may not be interconnected 
in autophagy regulation 
 
Ineffective degradation of polyQ aggregates induces chronic ER stress, which results in 
excessive autophagy (Kouroku et al. 2007). It has been previously shown, that GADD34 
plays an important role in the protection of a cell against mHTT, as it inhibits the mTOR 
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pathway which upregulates autophagy in mHTT-expressing cells, and increases cell 
survival at the 24 h timepoint (Hyrskyluoto et al. 2012).  
 
I show here that GADD34 may increase the expression of USP14 at the 24 h and the 48 h 
timepoints in the HD cell model. This data needs to be confirmed statistically. However, 
the findings in this thesis also suggest, that USP14 decreases the magnitude of ongoing 
autophagy in 120Q-expressing cells at the 24 h timepoint. The effect was dependent on the 
catalytic activity of the protein, as IU1 increased autophagy. Based on these findings it can 
be suggested, that the signaling routes between USP14 and GADD34 in HD are not 
interconnected in autophagy regulation. The effect of GADD34 on USP14 is diminished as 
the polyQ increases. This indicates that the role of USP14 is not as important in severe 
cases of HD as compared to normal CAG count (17Q and 18Q) in healthy individuals. It 
can be speculated that USP14 may inhibit autophagy, if UPS is the preferred degradative 
mechanism in HD cells.  
 
Catalytic activity of USP14 may increase ER stress in HD 
 
The expression of mHTT sensitizes cells to ER stress as it decreases the general protein 
turnover rate and inhibits ERAD proteins (Duennwald and Lindquist 2008, Lajoie and 
Snapp 2011). Reijonen et al. (2008, 2010) showed in the PC6.3 cell model, that the amount 
of p-eIF2α and p-JNK increased together with the increased polyQ tract of mHTT. In 
addition, it has been shown that 120Q transfection induces ER stress, which in turn leads to 
ERAD activation via dissociation of USP14 from IRE1α (Nagai et al. 2009). This led to 
the hypothesis that in the HD model IU1 itself has no effect on the ER stress level, as the 
effect of USP14 in ER stress has been seen previously with siRNA or loss of USP14 
(Nagai et al. 2009, Jin et al. 2012). However, the obtained data suggest that treatment with 
IU1 decreases ER stress in 18Q- and 120Q-expressing cells (the data is not statistically 
significant). It may be plausible, that the chain-trimming activity of USP14 in the HD 
model increases ER stress, possibly by enhancing the proteolytic activity (Lee et al. 2010). 
It is also possible, that IU1 changes the chemical surface and binding properties of USP14 
and thus alters its functionality beyond the chain-trimming activity. This data is 
controversial to other obtained ER stress-information in this thesis. It would be extremely 
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important to investigate this finding further to obtain more statistically solid information on 
the case.  
 Catalytic activity of USP14 is needed for SOD1 and 2 expression 
Previous studies indicate, that oxidative stress is involved in HD pathogenesis, as 
mitochondrial malfunction and energy production failure are associated with the disease 
(Browne and Beal 2004, Seong et al. 2005). It has been shown in the PC6.3 cell model, 
that mHTT downregulates the expression of mitochondrial antioxidants SOD2 and Trx2, 
and cytosolic antioxidant SOD1 (Kairisalo et al. 2007, Reijonen et al. 2010). The 
decreased SOD2 expression has also been seen in the R6/1 transgenic mouse model 
(Santamaria et al. 2001). 
 
As USP14 is an important molecule in neuronal cells, the chain-trimming activity is 
protective in HD, and this might be mediated by increased antioxidant expression (Lee et 
al. 2010, Wilson et al. 2002, Marshall et al. 2013, Chen et al. 2009). Hence, the hypothesis 
was that USP14 protects cells against oxidative stress in HD. My findings suggest, that the 
chain-trimming activity of USP14 may be protective against oxidative stress, as inhibition 
of the catalytic activity of the enzyme decreases the amount of SOD1 and SOD2 in the 
cell. The regulation of Trx2 seems to follow a different regulatory pathway, as IU1 
increases its amount in the control cells and in the 120Q-transfected cell. However, this 
data is lacking statistical evidence.  
 
Interestingly, Lee et al. (2010) have shown, that IU1 increased strongly the cells ability to 
survive when cells were under oxidative stress. Inhibition of the deubiquitinating function 
of USP14 by IU1 reduced the accumulation of oxidized proteins in human embryonic 
kidney 293 (HEK293) cells in a proteasome-dependent manner, suggesting that IU1 
promotes cell survival during oxidative stress. However, IU1 downregulated SOD2 only 
marginally in the HD cell model. It is possible, that USP14 might be able to affect the 
antioxidant expression only in the normal (non-disease) state in PC6.3 cells.  
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 Future prospects 
There is much that needs to be investigated in order to fully understand the function of 
USP14, such as investigating the ubiquitin linkage types. The discrimination between 
ubiquitin chain linkages is found to be different between Rpn11 and Uch37, and this may 
be the case in USP14 as well (Cooper et al. 2009, Jacobson et al. 2009). It is also important 
to determine the possible regulators of USP14 function, such as possible ubiquitin 
feedback regulation (Hanna et al. 2007). The research field involving USP14 and its novel 
inhibitor IU1 holds a promise of finding a treatment for neurodegenerative diseases such as 
HD, and thus it would be intriguing to continue the research initiated in this thesis. It is 
important to understand the role of USP14 in HD pathogenesis. During my experiments 
several ideas as how to continue this research arose. 
 
In this thesis I have provided preliminary guidelines for future experiments. The chosen 
direction should be verified by repeating the experiments ‒ in order to confirm the results 
and to obtain statistical significance. It seems that western blot is a very delicate method to 
operate with, being influenced by many factors. With this type of method it is crucial to 
have enough cell lysates to work with, but also to perform enough repetition to get the 
necessary statistical significance. The expression of the given proteins should be inspected 
also at the gene expressional level, for example by performing mRNA-based PCR (qPCR). 
Also, studies in primary neuronal cell cultures and the use of in vivo models should be 
considered, since they represent the disease more accurately than the PC6.3 cells. 
 
The results presented in this thesis indicate, that the deubiquitinating activity of USP14 
may protect cells against insoluble mHTT. Thus, it would be intriguing to continue the HD 
research with this protein. I have examined the effect of IU1 at the cellular level and with 
insoluble western blot assay, and it seems that it does affect the mHTT aggregate 
dynamics. It seems likely, that insoluble plaques are not cleared via autophagy, but this 
may not be the case with the soluble proteins. It is plausible that the two forms of mHTT 
are regulated separately, and differ with respect to the degradation pathways. Thus, it is 
crucial to focus the USP14 research on experiments involving the soluble mHTT as well. 
 
 
62 
 
One of the essential tests should be the measurement of cell death in USP14 
overexpression, inhibition, and depletion systems. My results indicate that the clearance of 
insoluble mHTT aggregates is mediated by USP14 in a proteasome-dependent manner. 
Thus, it would be important to study this finding further. One interesting approach could be 
to study the effects of USP14 overexpression and inhibition on ubiquitin homeostasis. The 
level of ubiquitin could be investigated, for example, in western blot with an antibody 
against ubiquitin. With this method the conjugated and free levels of ubiquitin could be 
observed. These experiments could sharpen the chain-trimming role of USP14 in HD, and 
could possibly provide a new therapeutic target for HD. 
 
To date it is not known what properties of mHTT confer the toxicity and contribute most to 
the pathogenesis of HD, but it has been suggested that truncated N-terminal fragments 
containing polyQ expansion are the most pathogenic forms of the protein (DiFiglia et al. 
1997, Ross and Tabrizi 2011). Although the role of the full-length form of mHTT in HD 
pathogenesis remains unknown, it is proposed to be less toxic (Gusella and MacDonald 
2006). As 18Q and 120Q plasmids in the HD model represent the N-terminal fragments, it 
is important to continue the USP14-focused research with this model. It would be equally 
important to use the full-length HTT constructs in the studies, since they represent the 
native protein, and may include important regulation sites that are affecting USP14. 
However, the expression of these proteins is exogenous and uncontrolled. The expression 
may not mimic the mechanisms involved in endogenous protein processing, which include 
ubiquitination and deubiquitination. Thus, the in vivo models of HD are optimal for USP14 
research after the suitable approaches are first tested by using in vitro systems. 
 
Stimulation of autophagy is considered one of the most potential approaches to treat HD, 
and currently there are several agents to induce it. It has been suggested, that upregulation 
of autophagy simultaneously with different agents could be the most effective strategy 
against pathogenesis (Harris and Rubinsztein 2011). Despite the suggestion that the 
catalytic activity of USP14 seems to be important for cell viability in HD, my experiments 
showed that IU1 increased autophagy in PC6.3 cells. The effect of IU1 should be further 
investigated in vivo in neuronal cells in the autophagy-inducing context. IU1 may 
upregulate yet unknown autophagy-related molecules and thus increase mHTT clearance 
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and cell viability. Different concentrations of IU1 could be tested. While I used 100 µM 
IU1, Lee et al. (2010) used 50 µM IU1. It could be, that a smaller concentration provides a 
different effect on the viability. If the experiments are replicated with siRNA against 
USP14, the effect of the deubiquitinating activity could be separated and examined. The 
ongoing autophagy should be measured at the protein level with antibodies against 
isoforms LC3-I and LC3-II in western blot. However, it must also be noted, that the 
conversion of LC3 does not measure the overall flux in the autophagy machinery, 
including lysosomes and the release of the end products (Klionsky et al. 2012). Different 
timepoints should also be tested, as it has been shown that 120Q downregulates the 
expression of mTOR at 24 h, but has no effect at 48 h (Hyrskyluoto et al. 2012). It is 
crucial to note that excessive autophagy may switch the pro-survival mechanism towards 
cell death. 
 
The data presented in this thesis regarding IU1 in ER stress is complex, as it seems that 
under non-stressed conditions the catalytic activity of USP14 upregulates ER stress, and in 
HD model it downregulates it. As it is suggested in this thesis, that USP14 may be 
involved in ER stress signaling routes in this HD model, it would be necessary to continue 
these examinations in order to further sharpen the function of USP14. The most important 
investigation would be to repeat the experiments with USP14 overexpression lysates. The 
expression level of Bip should also be measured, in order to confirm the results in ER 
stress initiation by USP14, and further determine its function. As only prolonged ER stress 
leads to cell death, different timepoints could be used in ER stress examinations, in order 
to separate the pro-survival and pro-death contribution of USP14 (Rutkowski and Kaufman 
2004, Boyce and Yuan 2006, Hetz 2012). The interconnection of GADD34 and USP14 
provides also an interesting target for study, as it could uncover a part of the overlapping 
regulation of ER stress and autophagy. The investigations could be replicated with USP14 
overexpression lysates and IU1 treatment in which GADD34 expression levels are 
measured.  
 
In this thesis I show that USP14 has a role in oxidative stress, since there is a trend in 
regulation that IU1 decreases SOD1 and SOD2 expression. It is crucial to continue this line 
of research with USP14 overexpression, as it may prove to be beneficial to the cell. One 
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study point could be ROS measurements, since Reijonen et al. (2010) have seen, that 
mHTT increases ROS production in 120Q-expressing cells. It would be important to 
replicate the experiment with USP14 both in overexpresssion and inhibition systems. Also, 
it would be interesting and important to examine the NF-κB levels in the USP14 system, as 
it has been previously shown that NF-κB is downregulated by mHTT (Kairisalo et al. 
2007, Reijonen et al. 2010). Interestingly, it has been shown that NF-κB is downregulated 
in ER stress (Reijonen et al. 2010). This could provide interesting new information how 
USP14, UPS, ER stress and oxidative stress are interconnected in the mHTT model. 
 
The polyQ expansion leading to misfolding and aggregation of the given protein is seen in 
several other neurodegenerative diseases besides HD, such as Alzheimer’s disease and 
Parkinson’s disease (Rubinsztein 2006). The mechanisms of pathogenesis among these 
diseases have several common denominators. It is believed that impaired UPS and 
autophagy contribute to the pathogenesis (Rubinsztein 2006, Wong and Cuervo 2010, 
Dennissen et al. 2012). Elevated oxidative and ER stress are also associated with the 
pathogenesis of human neurodegenerative diseases (Lindholm et al. 2006). It is captivating 
to speculate that the findings in this thesis could be applied in the investigation of these 
diseases in future research. 
 Conclusions 
The hypothesis that was tested in this thesis was that USP14 increases survival against HD 
in the PC6.3 cell model. Based on the previous research and the data obtained from my 
experiments in this thesis, I propose that the chain-trimming activity of USP14 is indeed 
self-protective for PC6.3 cells in both healthy control cells and in the HD cell model 
(Figure 19).  
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Figure 19. Schematic summary of the suggested function of USP14 in healthy PC6.3 cells and in the 
HD model. USP14 decreases the amount of insoluble mHTT aggregates in a deubiquitinating activity- and 
autophagy-dependent manner, suggesting that USP14 enhances the clearance of the protein via UPS. When 
the enzymatic activity of USP14 is inhibited autophagy is upregulated, indicating that there may be reciprocal 
regulation of these degradative pathways. GADD34, that is associated with cytoprotective autophagy and cell 
survival, regulates USP14. This may indicate, that USP14 is one of the proteins that are needed for cell 
survival. When the catalytic activity of USP14 is inhibited, the healthy cell becomes more vulnerable to 
insults, as its ER stress level increases and antioxidants SOD1 and SOD2 decrease. It is plausible that the 
enzymatic activity of USP14 inhibits ER and oxidative stress. 
 
 
The findings from USP14 overexpression studies and inhibition studies indicate, that 
USP14 enhances the clearance of mHTT via UPS. They also show that inhibition of the 
catalytic activity of USP14 stimulate ER stress response and decrease antioxidant 
expression. Taken together the data indicate that the catalytic activity of USP14 increases 
survival of a cell and is an important mediator in HD pathogenesis. However, these 
findings can be used only as a guideline and they need to be statistically confirmed.  
 
It is likely that UPS and autophagy are interconnected in HD pathogenesis, and it seems 
that USP14 is one of the molecules that is able to regulate both of these degradative 
pathways. However, it is plausible that USP14 regulates several signaling routes in 
neurons. It may be possible, that not separate actions, but the cumulative effect of USP14 
functions determines the consequences of the protective or non-protective role of the 
molecule in HD.  
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The aim of my research was to map directions for future USP14 research by model and 
probes that had been set and tested previously. During this period the model system 
operated satisfyingly and provided interesting new data from diverse routes of HD 
pathogenesis and USP14 function.  
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